

Exploring the Painless Nature and Potential Mechanisms of Asymptomatic Irreversible Pulpitis: A Narrative Review



Daniela Paola Cabrera-Abad¹, Verónica Cristina Jara-Vergara¹ and José Luis Álvarez-Vásquez^{1,*}

¹Department of Endodontics, Faculty of Dentistry, University of Cuenca, 010107 Cuenca, Ecuador

Abstract:

Background: Considering the extensive innervation of the pulp tissue, asymptomatic irreversible pulpitis (AIP) or “silent pulpitis” represents a confounding clinical condition. Previous studies have attributed the painless nature of AIP to the inhibition of pulpal nociceptors by local endogenous analgesics. However, there is a lack of recent information concerning its painless nature, and paradoxically, patients with dental pain are diagnosed with AIP daily worldwide. In addition, no recent review has explored the potential AIP-related mechanisms.

Objective: This narrative review aims to explore and update the potential mechanisms involved in the painless nature of AIP to improve our current understanding of the asymptomatic character of this clinical condition.

Methods: An electronic search was performed in the PubMed and Scopus databases, using as search terms “asymptomatic irreversible pulpitis,” “dental pulp,” “endogenous opioids,” “endogenous cannabinoids,” “somatostatin,” “GABA,” “bombesin,” “cortistatin,” “galanin,” and “specialized pro-resolving lipid mediators.”

Results: Endogenous opioids, G protein-activated inwardly rectifying K⁺ channels, endogenous cannabinoids, γ -aminobutyric acid, and neuropeptides (*i.e.* somatostatin, cortistatin, galanin, and bombesin) could be involved in AIP-related analgesia. Additionally, specialized pro-resolving lipid mediators, such as lipoxins, resolvins, maresins, and protectins, as well as oxytocin, phoenixin, opiorphin, and adipokines, could also be involved in this clinical condition.

Conclusion: This narrative review provides updated information on the potentially involved mechanisms in AIP. Nevertheless, the precise mechanisms responsible for the lack of symptoms in AIP remain to be elucidated, and further research is warranted.

Keywords: Asymptomatic irreversible pulpitis, Analgesia, Endogenous opioids, Endogenous cannabinoids, Neuropeptides, Phoenixin.

© 2024 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Address correspondence to this author at the Department of Endodontics, Faculty of Dentistry, University of Cuenca, 010107 Cuenca, Ecuador; E-mail: jose.alvarezv@ucuenca.edu.ec

Cite as: Cabrera-Abad D, Jara-Vergara V, Álvarez-Vásquez J. Exploring the Painless Nature and Potential Mechanisms of Asymptomatic Irreversible Pulpitis: A Narrative Review. Open Dent J, 2024; 18: e18742106281444. <http://dx.doi.org/10.2174/0118742106281444240219050149>



Received: September 09, 2023

Revised: December 29, 2023

Accepted: January 25, 2024

Published: February 23, 2024



Send Orders for Reprints to reprints@benthamscience.net

1. INTRODUCTION

The dental pulp is a highly vascularized, innervated connective tissue that provides vitality and sensitivity to teeth [1, 2]. This tissue experiences inflammatory reactions in response to dental caries, restorative procedures, dental trauma, and periodontal disease [3] — the first being the main threat to dental pulp [4]. However,

pulpitis is the most common inflammatory disease in humans and other mammals [5] that can be reversible or irreversible. Irreversible pulpitis can be symptomatic or asymptomatic [6].

Considering the extensive nerve plexus of the pulp tissue, asymptomatic irreversible pulpitis (AIP) or “silent pulpitis” is a confounding clinical condition [7]. Patients

do not experience pain (6) despite inherent inflammatory processes in the affected tooth. Several studies have identified local analgesic agents in the dental pulp, including endogenous opioids [8-10], cannabinoids [11, 12], gamma-aminobutyric acid (GABA) [13, 14], and somatostatin [10, 15]. These agents could inhibit pulpal nociceptors and may be responsible for the asymptomatic nature of AIP [7].

Despite these studies investigating the dental pulp, there is a lack of updated literature reviews that explore the factors involved in the asymptomatic nature of AIP, and the most recent foundational study on the painless nature of AIP dates back two decades [16]. Moreover, patients with dental diseases are diagnosed with AIP on a daily basis worldwide. Therefore, this narrative review aimed to compile updated information on potential factors involved in the mechanisms of analgesia underlying AIP to improve our current understanding of its painless nature and to provide insights for future studies elucidating the precise mechanisms underlying the lack of symptoms in AIP.

2. MATERIAL AND METHODS

We searched the available literature in the PubMed and Scopus databases to identify relevant articles published up to January 25, 2022, describing the expression of ligands and/or receptors or other factors that potentially regulate the asymptomatic nature of AIP. The following search terms were used: “asymptomatic irreversible pulpitis,” “dental pulp,” “endogenous opioids,” “endogenous cannabinoids,” “somatostatin,” “GABA,” “bombesin,” “cortistatin,” “galanin,” and “specialized pro-resolving lipid mediators.” Only articles published in English were included in the present study. The search was limited to clinical trials, *in vitro* studies, literature reviews, systematic reviews, and textbook chapters. Interim reports, abstracts only, letters, brief communications, studies that did not focus on the asymptomatic nature of AIP, and duplicated works were excluded. Subsequently, the titles and abstracts of relevant articles were reviewed, and a manual search of the references of each selected article was performed to complement the electronic search. Further, endodontic journals were examined to identify relevant articles “in press” or in “early view” status.

3. POTENTIAL FACTORS INVOLVED IN ANALGESIA DURING AIP

Factors that could potentially be involved in the mechanisms of analgesia underlying AIP include endogenous opioids, G protein-activated inwardly rectifying K⁺ channels (GIRK), endogenous cannabinoids, γ-aminobutyric acid (GABA), neuropeptides (somatostatin, cortistatin, galanin, and bombesin), and specialized pro-resolving lipid mediators (*i.e.* lipoxins, resolvins, and maresins). We also included a section on miscellaneous factors that could potentially be involved in AIP, such as bacteria and their antinociceptive effects, oxytocin, phoenixin, opiorphin, and adipokines. All but bacteria are

endogenous biomolecules potentially involved in the painless nature of AIP. The ligands/receptors of these biomolecules have already been identified in the dental pulp tissue and/or the trigeminal ganglion (TG). However, in some cases, information is not yet available (Table 1).

3.1. Endogenous Opioids

The opioid system functions as an endogenous mechanism of antinociception through three pathways: inhibition of nociceptors at the supraspinal level, inhibition of nociceptors at the level of the dorsal horn of the spinal cord, and activation of the descending inhibitory pathways [15]. This system is distributed in both the central nervous system (CNS) and peripheral nervous system (PNS) [17-20]. It is comprised of endogenous opioid peptides (EOP) (*i.e.*, enkephalins, dynorphins, β-endorphins, and nociceptin/orphanin FQ) [17] released by T- and B-lymphocytes, monocytes, macrophages, and granulocytes [21-24]; and opioid receptors (OR) that are located in the nerve endings of the primary afferent fibers [25, 26]. Met-enkephalins, dynorphins, and β-endorphins have been found in the dental pulp [10, 27, 28]; however, the presence of nociceptin/orphanin has not yet been demonstrated.

The receptors found in the afferent sensory nerves are μ (MOR), δ (DOR), and κ (KOR) [17, 23, 29-32], along with the nociceptin/orphanin receptor (NOR), also known as the orphan opioid receptor-like receptor (ORL) [17, 33]. ORs, especially DOR, are involved in neuroprotection against hypoxia or ischemia [34-37]. They also inhibit voltage-gated Ca²⁺ channels [38], reduce the release of neurotransmitters [17], and allow neuronal hyperpolarization that is mediated by K⁺ channels [39]. The presence of MOR [9] and DOR [40] in the dental pulp has been confirmed; however, the KOR expression has not yet been demonstrated.

Under normal conditions, the ORs are inaccessible due to the perineural barrier [41-43]; however, this is altered in initial inflammatory conditions that allow for the passage of ligands to their receptors [30]. In late inflammatory stages, the number of ORs increases, along with their axonal transport to the periphery [9, 24] and sprouting of new nerve endings [44, 45] that would explain the opioid analgesic activity in inflamed dental pulps [9]. In these states, β-endorphins become unstable due to their rapid metabolism; therefore, the resulting analgesia could be induced by their fragments after their biotransformation [46]. In contrast, a previous study showed that antinociception failed to increase despite the increased leukocyte recruitment, which could be attributed to the low amount of ORs in the early inflammatory stage [47]. The duration of inflammation could be a decisive factor in terms of the analgesic capacity of the endogenous opioid system, such that in both types of irreversible pulpitis (symptomatic and asymptomatic), an inflammatory process is established; however, pain is absent in the latter scenario. In endogenous analgesia, the number of leukocytes, ORs, duration of inflammation, and binding efficiency of ORs

with G-protein in neurons interact in a simultaneous manner [45, 48, 49].

Central and peripheral ORs interact in the initial inflammatory stages [47, 50-52]; however, in the late stages, only peripheral ORs function [23, 53, 54], demonstrating high participation of peripheral opioid mechanisms as inflammation advances and becomes more severe [48, 51, 55, 56]. Moreover, during chronic inflammation, at the central level, changes in the ORs are not observed, but the levels of EOP increase [32]. Therefore, further studies are required to determine the differences in central responses that occur at different times and in different types of dental injuries [57].

Bradykinin stimulation [58], orthodontic movements [59], and cavity preparation [60] increase the EOP levels in the dental pulp [15, 55, 61]. Moreover, other substances exert an antinociceptive effect as a secondary function by stimulating the release of EOPs in a similar manner to the effects exerted by substance P (SP) whose N-terminal fragment acts as a ligand for MOR [62, 63], calcitonin gene-related peptide (CGRP) that suppresses IL-2 production [64], and IL-4 that promotes change in the phenotype of macrophages from M1 to M2 and stimulates M2 to produce EOP in injured nerves [65]. Additionally, interleukin 1 β (IL-1 β), corticotropin-releasing factor (CRF) [66], norepinephrine, and CXCL2/3 stimulate the release of EOP by leukocytes [21, 50, 67-72], and thus, exert a peripheral analgesic effect [50, 69-71, 73]. Moreover, some opioid agonists exert anti-inflammatory effects, probably involving ORs on immune cells [74].

In contrast, M2 macrophages can help in resolving inflammatory pain by transferring their mitochondria to the neurons of the dorsal root ganglion (DRG) and stimulating the switch from neuronal glycolytic metabolism to more oxidative metabolism, which in turn regulates the neuronal activity and allows for the resolution of inflammatory pain away from the inflammation site [75]. An increase in the M2 levels has been observed in the TG as pulpitis progresses, showing anti-inflammatory effects [76]. Moreover, this analgesic effect could be attributed to the secretion of IL-10 because of its anti-inflammatory action [77-81] and a reduction in the expression of voltage-gated sodium channels and a number of currents sensitive to tetrodotoxin [82]. However, the resolution of inflammation is insufficient to resolve the pain [80].

3.2. GIRK

GIRK are G protein-activated effector ion channels [83] that participate in opioid-mediated antinociception in the CNS and PNS *via* hyperpolarization of the neuronal membrane, which in turn inhibits the propagation of action potentials [84-90]. At the spinal cord level, these receptors contribute to the analgesic effects of MOR and DOR but not those of KOR [88]. Furthermore, GIRK channels are crucial for galanin action, as GalR1 and GalR3 open the K⁺ channels. For neuropeptide Y, which presynaptically depresses the miniature excitatory synaptic currents through the Y2 receptor, somatostatin

activates the GIRK channels of SST4 receptors [91-95].

The GIRK 1 and 2 receptors are expressed in the TG neurons, thus contributing to peripheral opioid analgesia in the craniofacial region [96]. Therefore, these channels could be present in the dental pulp; however, to date, no study has confirmed this hypothesis.

3.3. Endogenous Cannabinoids

The endogenous opioid and cannabinoid systems are involved in antinociception through different pathways [97-104]. Moreover, they activate the G-protein-coupled receptors (GPCR) and can interact either directly (receptor heteromerization) or indirectly (cross-signaling) [97, 98, 105]. Moreover, cannabinoid receptors (CBRs) activate GIRK, which in turn reduces the release of neurotransmitters in the opioid system [106]. The endocannabinoid system has receptors (CB1R and CB2R), endogenous ligands (anandamide and 2-arachidonylglycerol), and enzymes that degrade and synthesize the latter, performing functions at the central and peripheral levels [107, 108]. This system is expressed in both the ascending and descending pain pathways, producing antinociception at the supraspinal, spinal, and peripheral levels [102, 109-112]. Additionally, lipopolysaccharides (LPS) increase the levels of anandamide and inhibit the enzyme fatty acid amide hydrolase (FAAH) in the lymphocytes [113], and increase the levels of 2-arachidonylglycerol (2-AG) in the macrophages and platelets [114].

CB1R and CB2R are mainly expressed in the nervous and immune systems, respectively [115-119], and the cells of these systems secrete endocannabinoids [23, 120, 121]. CB1Rs have been identified in various areas related to pain in the CNS, where they regulate signals from neurons originating from the nociceptive regions of the spinal cord, producing antinociception [110-112, 118]. CB1R of the ventrolateral periaqueductal gray matter (vlPAG) aids in modulating the nociceptive signals from the TG nerve, specifically in capsaicin-induced pulpal pain [122]. The exact mechanism of this modulation is unclear; however, CB1R in the PAG interacts with other systems to modulate the nociceptive signals [123, 124], such as orexin 1 receptors (OX1Rs). When activated, these receptors induce the release of 2-AG, which inhibits the release of GABA through the pre-synaptic CB1R—a phenomenon known as disinhibition [123]. Tonic inhibition of GABAergic transmission activates the vlPAG; thus, activating the descending pain inhibition pathway [125]. This demonstrates the antinociceptive effects of orexin-A on the vlPAG and its relationship with the endocannabinoid system [123].

The CBR signaling pathway acts through the inhibition of cyclic-AMP formation and modulation of Ca²⁺ and K⁺ channels [126]. Different ligands differentially activate these signaling pathways through CB1R and CB2R—which is termed the “biased signaling” [127]. Further studies at the pulp level are suggested as this signaling may preferentially provide higher analgesia. Additionally, the molecular mechanisms underlying the antinociceptive

and antihyperalgesic effects of CBRs remain unclear [115]. Endocannabinoids, such as anandamide, 2-AG, and the other less-studied subtypes, including N-arachidonoyl-dopamine (NADA), noladin ether, and virodhamine, interact with receptors other than CB1R and CB2R [105, 128, 129].

In contrast, transient receptor potential vanilloid subtype 1 channels (TRPV1) are activated by anandamide and NADA and are co-expressed with CB1R and CB2R in some tissues, including the dental pulp [128, 130]. This co-expression or “cross-talk” between CBR and TRPV1 may be relevant in pulpal analgesia. It has long been known that only CBRs attenuate and TRPV1 increases nociception. However, studies have shown that TRPV1 activation potentiates the supraspinal pain inhibitory pathways, and desensitization of TRPV1 produces analgesia [131, 132]. Pre- and post-synaptic activation of TRPV1 or pre-synaptic activation of CB1R stimulates the output excitatory neurons through glutamate release or disinhibition of GABA tonic control, respectively, at the vlPAG level. This leads to glutamate release in the rostral ventromedial medulla (RVM) and activation of the “off” neurons in this area, with a subsequent antinociception [133, 134]. However, further studies are required to analyze the factors that activate these pathways.

TRP channels also induce peripheral antihyperalgesia and antinociception [135, 136]. However, their mechanism of action is complex, as they generate incoming ionic currents more associated with nociception. Partial activation of these channels may not necessarily generate neuronal excitation [137-139]. The incoming currents could fail to reach threshold levels to excite the nociceptors, or the slow depolarization of the membrane potential may inactivate these channels [140].

CB1R and CB2R expression in the dental pulp of humans and rats has been previously demonstrated [10, 11, 130, 141-143]. CB2R is expressed in the human pulp cells [130, 142] and myofascial fibroblasts [144], whereas CB1R is preferentially expressed in odontoblasts, odontoblast-like cells, and pulpal nerve fibers [11, 145]. Although the expression of CBRs has not been shown in dental pulp fibroblasts, it has been reported that fibroblasts have the necessary enzymes to produce endocannabinoids and act in an autocrine or paracrine way when interacting with leukocytes [144, 146, 147]. A previous study showed that there were no statistically significant differences in the expression of CB1R between painful and non-painful dental pulps [11].

In contrast, CB1R may be activated by stretching in the absence of a ligand [119], wherein hydrostatic pressure may directly activate OR and CBR, releasing endorphins and endocannabinoids, as has been reported at the PAG level [148]. In the dental pulp, an increase in pressure during an inflammatory process may activate these receptors, although this remains to be explored. However, the role of CB2Rs and their agonists has been investigated in pulpal antinociception [149] and in animal models of acute, chronic, and neuropathic pain [150].

CB2R agonists can inhibit inflammatory pain through their anti-inflammatory effects [151, 152]. Moreover, the expression of cytokines and CBR have a reciprocal regulatory relationship. Thus, the activation of these receptors in macrophages inhibits the production of proinflammatory cytokines [153], thus allowing the change from immune responses mediated by Th1 (proinflammatory) to Th2 (anti-inflammatory) through the CB2R [154]. Moreover, IL-4 increases the CB1R expression in leukocytes [155], and IFN- γ and IL-12 reduce the FAAH activity [113]. Taken together, the increase in CBR expression by cytokines could be a mechanism of autoregulation of inflammation [156].

3.4. GABA

GABA neurotransmitter plays a primary inhibitory role in the CNS and PNS [157-161]. When released at the neuronal synapses, it activates different classes of receptors or returns to the nerve terminals *via* a Na⁺-dependent transporter [158-160]. Ionotropic receptors (GABA_A and GABA_C) participate in rapid synaptic transmission and modulate neuronal activity by gating the chloride ions [13, 159], hyperpolarizing the neuronal membranes, and inhibiting the propagation of action potentials, leading to short-term, fast-acting inhibitory currents [157, 160]. In contrast, the slow-acting metabotropic receptors (GABA_B) belong to the GPCR superfamily and exert inhibitory actions through the inhibition of voltage-gated Ca²⁺ channels and GIRK activation [162-167]. These receptors have been found in the dental pulp tissue [13] and TG [163]. Furthermore, GABAergic neurons are activated at the trigeminal nuclear complex during tooth pulp stimulation [161].

However, inflammation, necrosis, or areas of pulpal hypoxia can increase the GABA levels above the nominal levels at rest, which may explain the absence of symptoms in these pulps [12, 13]. Neuroinflammation can be modulated by GABAergic signaling [157], as GABA_B receptors are involved in pain management and analgesia; thus, GABA and GABA_B receptors present in the human pulp may also be involved [164]. The clinical importance of peripheral GABA_B receptors may be related to the peripheral analgesic effects of GABA_B agonists that modulate or attenuated nociceptive behavior in the animal models of pain [165]. In a previous study [166], isovaline, baclofen, and GABA attenuated allodynia induced by prostaglandin E2 injection. Another study revealed that baclofen suppressed pain in small-diameter TG neurons in rats [162].

In contrast, GABAergic interneurons mediate the endogenous release of 5-hydroxytryptamine (5-HT). The 5-HT₃ receptors are involved in antinociceptive effects [167] that are attenuated by the opioid antagonist naloxone, suggesting that these neurons may be associated with endogenous opioids [168].

3.5. Neuropeptides: Somatostatin, Cortistatin, Galanin, and Bombesin

Neuropeptides play a major role in the perception of pain [169], but some can mediate analgesic mechanisms

[170]. In this section, we describe the potential analgesic roles of somatostatin, cortistatin, galanin, and bombesin in AIP.

3.5.1. Somatostatin (SST)

SST is a peptide hormone [171-173] that is widely distributed in the CNS and peripheral tissues [171, 174] and is produced by neurons and neuroendocrine, inflammatory, and immune cells in response to ions, nutrients, neuropeptides, neurotransmitters, hormones, growth factors, cytokines [173], and noxious heat or chemical stimuli [175]. There are two SST isoforms, SST-14 and SST-28, that differ in the number of amino acids [175-177] and five GPCR-type receptors (SSTR 1-5) [178].

SST performs antinociceptive functions [179-182] by affecting neurotransmission through its receptors, decreasing the conductance of voltage-gated Ca^{2+} channels [172, 183], and activating K^{+} channels [184-186]. SST decreases neurogenic inflammation [175] due to its inhibitory action [175, 187, 188] by decreasing the release of IFN- γ , reactive oxygen species, CGRP [175], SP [189], and immunoglobulins from B-cells [190]. Moreover, SST can regulate the pulpal blood flow [191] as the peptidergic nerves containing SST are distributed near the blood vessels [10, 192-194].

3.5.2. Cortistatin (CORT)

CORT, a cyclic neuropeptide, is predominantly expressed in the cerebral cortex [195-197], spinal cord neurons, GABAergic inhibitory interneurons [198-200], immune cells (lymphocytes, monocytes, macrophages, and dendritic cells) [201, 202], and to a lesser extent in endothelial cells, endocrine cells, peripheral nociceptive neurons, and smooth muscle cells [203] in response to noxious stimuli, cytokines, and tissue injury [197, 203].

CORT binds with a high affinity to different receptors, mainly SSTR 1-5 [192, 204], ghrelin receptor (GHSR1) [196, 197], and an unidentified selective CORT receptor [198]. It shares several functions with SST [205], such as suppression of nerve function and inhibition of cell proliferation [196, 206]; however, it has other functions, such as sleep induction, reduction of locomotor activity, and deactivation of inflammatory/autoimmune responses [196, 203, 206, 207]. Regarding adaptive immunity, CORT acts on CD4 T-lymphocytes, participates in the inhibition of differentiation and activation of Th1 and Th17 lymphocytes, and induces differentiation and activation of Th2 and Treg lymphocytes. As for innate immunity, CORT acts on macrophages/monocytes and participates in the inhibition of proinflammatory mediators, such as CGRP [205], TNF, IL-6, IL-12, IL-1, NO, GM-CSF, and CK, and increases the levels of IL-10 [208, 209]; thus, exerting anti-inflammatory effects. In contrast, its deficiency can exacerbate inflammatory pain responses [197, 210].

Finally, CORT is capable of deactivating microglia and astrocytes in an inflammatory environment [197, 211]. Activated glial cells play a critical role in the development and maintenance of nociceptive responses, especially at

the spinal cord level [211]. Thus, CORT regulates inflammation-induced pain through deactivation, particularly by preventing the development of chronic pain. It also relieves hyperalgesia and allodynia and acts as a neuroprotector and neuroregenerator [205]. Furthermore, CORT mRNA and protein are detected in mature and newly developing odontoblasts. Thus, SSTR1 and CORT may have important functions in the regulation of pulpal inflammation and communication between odontoblasts and the nervous system [212] and may be involved in antinociceptive processes at the pulpal level. However, further studies are needed to confirm these hypotheses in the dental pulp.

3.5.3. Galanin (GAL)

GAL, a neuropeptide widely distributed in the CNS and PNS [213-216], is present in non-neuronal cells, such as keratinocytes, sweat glands, macrophages, and blood vessels [217]. It is expressed by immune cells during inflammation in an attempt to restore homeostasis [218] and exerts its physiological effects through three types of GPCRs [216, 219], namely GalR1, GalR2, and GalR3 [216, 220-224]. Previous studies have suggested that GAL and its receptors may be involved in the transmission and modulation of nociceptive information in the nervous system [225-230].

GAL has an antinociceptive effect [228, 231-235] via activation of GalR1 [226, 236-238] and GalR3, which causes neuronal hyperpolarization in response to increased K^{+} conductance [239], and also favors the release of enkephalins and endorphins in the primary afferent neurons that innervate the dental pulp [240]. The immunoreactivity of GalR1 has been observed in the axoplasm of unmyelinated nerve fibers (type C and A δ) of the dental pulp [241, 243]. However, it can induce pronociceptive effects [224, 243] through the action of GalR2 [226, 236-238, 244-246] and activation of phospholipase C-protein kinase C pathway [247]. Nevertheless, the GAL action differs according to its concentration, where the activation of GalR2 changes from a Gq pathway (low GAL concentration) to a Gi/o-dependent pathway (high GAL concentration); therefore, it changes from a pro- to an antinociceptive-type signaling pathway [248]. However, the latter has not yet been observed in the dental pulp tissue.

3.5.4. Bombesin (BN)

The endogenous peptide, BN [249], and its homologues, neuromedin B (NMB) and gastrin-releasing peptide (GRP) are important neuromodulators in the brain [250, 251]. They function through three subtypes of G protein-coupled hepta-helical receptors, namely BB1, BB2, and BB3. NMB and GRP show high affinity and serve as endogenous ligands for BB1 and BB2 receptors, respectively [250], whereas BN activates both receptors [251], and BB3 is an orphan receptor with low affinity for all these peptides.

BN increases the presynaptic release of GABA by facilitating the entry of extracellular Ca^{2+} [250], depolarizing

izes GABAergic interneurons at the presynaptic level through the inhibition of KIRs and K⁺ conductance, and increases the input resistance of interneurons. This suggests that BN reduces the conductance of the neuronal membrane [250]. Its antinociceptive action may be related to the release of GABAergic interneurons.

A previous study [13] demonstrated the significantly higher presence of specific GABA-like and BN/GRP-like immunoreactivity in the pulps of asymptomatic carious teeth than in normal teeth. Both peptides have been implicated in antinociception [13] and have been reported in TG neurons [252]. Their immunoreactivity has been observed within the pulpal nerves and pulp fibroblasts [13].

3.6. Specialized Pro-resolving Lipid Mediators (SPMs): Lipoxins, Resolvins, Maresins, and Protectins

The SPMs actively resolve inflammation to avoid the development of a chronic condition [253]. These endogenous lipid mediators act as immune response modifiers and selectively modulate and reduce the host response. They resolve inflammation [254] by clearing debris and infectious agents, reducing pain, and restoring the function of damaged tissues [255].

In contrast, several studies support the potent role of SPMs in reducing the different types of pain, including inflammatory and neuropathic pain [256-263], through GPCRs and different downstream mechanisms, such as the regulation of inflammatory mediators, TRP channels, and central sensitization [264].

Studies with animal models indicate that SPMs can reduce inflammatory, postoperative, and neuropathic pain *via* immune, glial, and neuronal modulation [265]. Additionally, SPMs are produced in small amounts *in vivo* (nano- or picograms), and thus, the doses used in experimental studies are of equal magnitude [262, 266, 267]. Despite the low doses, the analgesic and anti-inflammatory potency of SPMs is evident. Those doses are not comparable with the milligrams or grams used with analgesic agents, such as nonsteroidal anti-inflammatory drugs or opioids [268, 269].

Furthermore, SPMs could potentially participate in the asymptomatic nature of AIP *via* the resolution of inflammation and their anti-inflammatory effects. Nevertheless, such issues need to be clarified by well-established pulpal pain models. However, technical barriers pertaining to the instability, complex and delicate physicochemical nature, and metabolic inactivation of SPMs must be overcome [253].

3.7. Miscellaneous Mechanisms

3.7.1. Bacteria and their Antinociceptive Effects

Inflammation-induced pain is an adaptive response designed to protect the body from further injuries [270]. However, disease scenarios vary because some pathogens can block, reduce, or modulate pain during the disease

cycle [271]. For instance, *Porphyromonas gingivalis* [270] is associated with destructive periodontal disease [270, 272], dental caries [273], endodontic infections, and odontogenic abscesses [274]. It exerts antinociceptive effects [270], where its LPS increases the levels of the potent anti-inflammatory cytokine IL-10 [270] and stimulates the peptide derived from human telomerase (GV1001) that has an anti-inflammatory effect without affecting the cell viability in the human dental pulp, as it allows for downregulating the expression of TNF- α and IL-6 [272]. However, the antinociceptive role of this bacterium has not yet been studied in AIP; thus, more studies are required.

Metagenomic studies have revealed that the human microbiome can generate many bioactive molecules, including histamine, epinephrine, and GABA [275-277]. Therefore, the possible antinociceptive actions of bacteria, such as *Lactobacillus* species [278, 279] (*Lactobacillus acidophilus* NCFM), induce the expression of the cannabinoid and μ -opioid receptor in the intestinal epithelial cells [280]. Whereas, *Bifidobacterium* species, such as *B. dentium*, also produce GABA [281-283], making neurons less likely to reach the threshold depolarization level [283].

In contrast, *M. ulcerans* can secrete mycobacterial polyketide mycolactone to induce analgesia by activating angiotensin II type 2 receptors (AT2R) and inducing hyperpolarization through activation of K⁺ channels in nociceptors [271, 284]. Additionally, in acute staphylococcal infections [285], CGRP, GAL, and somatostatin can suppress TNF- α release from *S. aureus*-stimulated or heat-killed lipoteichoic acid macrophages. This indicates that the presence of these bacterial agents may induce the production of other substances that reduce inflammation and have analgesic action.

Finally, in the dental pulp, LPS from bacteria modulates the nociceptive activity through TLR4-mediated sensitization of TRPV1 to nociceptors [286]. Moreover, LPS could be detrimental if pathogenic factors suppress nociception because they can evade host detection and allow for the silent spread of infection.

3.7.2. Oxytocin (OXT)

OXT, a hormone and neuropeptide, induces antinociception [287-290] and participates in the endogenous opioid system [288]. At the TG level, the expression of OXT receptors (OXTR) in the nociceptive neurons (small A- δ fibers) has been confirmed [289, 290], and their expression increases during chronic inflammation [291]. Both OXT and vasopressin (V1A) and their associated receptors, namely OXTR and V1AR, respectively, induce analgesia in the sensory neurons [292-295], possibly because the peripheral antinociceptive action of vasopressin is due to an increase in the function of the GABAA receptor, inhibition of the acid-sensitive ion channels [293, 296], and OXT by the direct desensitization of TRPV1 [297]. Therefore, the analgesic action may also be present in the dental pulp due to its expression in the TG. However, this requires further investigation.

3.7.3. Phoenixin

The neuropeptide, phoenixin, is expressed in the TG sensory neurons that may not be associated with antinociception in thermal pain models. However, phoenixin is associated with antinociception in the visceral pain models [298]. Phoenixin suppresses LPS-induced inflammation in the dental pulp cells, and its anti-inflammatory effects have been demonstrated by confirming the expression of its receptor, GPR173, in the human pulp cells [299]. Further studies should address its anti-inflammatory and potential analgesic properties.

3.7.4. Opiorphin

Enkephalins have a stronger analgesic effect than morphine, but this effect does not last because of the degrading enzymes, such as neutral endopeptidase and aminopeptidase-N [300]. Opiorphin is a peptide that acts as an inhibitor of these enzymes, thus prolonging the effects of enkephalins [300-302].

It is present in the blood, urine, semen, milk, tears,

and saliva, although its highest concentrations have been observed in tears and saliva [303]. The more intense the pain due to inflammation is, the more the salivary opiorphin exists; however, its expression remains to be evaluated in the pulp tissue.

3.7.5. Adipokines

Adipokines play multiple physiological and pathological functions in the dental pulp, and some of them exert anti-inflammatory activity, such as adiponectin and ghrelin [304]; therefore, both adipokines could reduce pain in AIP due to their inherent anti-inflammatory activity. Although several adipokines have recently been identified [305], only a few of them have been studied in the pulp tissue [304]. Thus, their potential involvement in pulp inflammation and pain warrants further investigation.

Table 1 summarizes all the aforementioned factors that are potentially involved in AIP, their ligands/receptors identified in the dental pulp tissue and/or TG, and their potential analgesic-related mechanisms.

Table 1. Potential factors involved in AIP.

Potential Mechanism	Ligands Identified in the Dental Pulp or TG	Receptors Identified in the Dental Pulp or TG	Role Confirmed in AIP-related Analgesia	Potential Mechanisms Involved in the Painless Nature of AIP
Endogenous opioids	Dental pulp [8, 10, 15, 27, 28, 58-60].	Dental pulp [9, 40].	No	<ul style="list-style-type: none"> - Negative regulation of neurogenic inflammation [8]. - ORs up-regulation in late inflammatory stages, along with their axonal transport to the periphery [9, 24, 32, 57]. - Peripheral analgesia by the up-regulated expression of ligands and/or receptors [30-32]. - Anti-inflammatory effects [74]. - Pain modulation within the inflamed tissue by opioid peptides released from the immune cells [21-24, 47, 48, 51, 52, 67-72, 80]. - High involvement of the peripheral opioid mechanisms as inflammation advances [48, 51, 55, 56].
GIRK	N/A	TG [96].	No	Peripheral opioid-mediated analgesia [85, 87-89, 96].
Endogenous cannabinoids	N/A	Dental pulp [10, 11, 130, 141-145, 149].	No	<ul style="list-style-type: none"> - Anti-inflammatory and analgesic effects [136, 145]. - GIRK activation reduces the release of neurotransmitters [106]. - Increased analgesia through biased signaling [127]. - CB1 inhibits the neurotransmitter release on nerve terminals and CB2 modulates cytokine release on immune cells [130]. - Inhibition of inflammatory pain by anti-inflammatory effects [151-154]. - Cross-talk between CBR and TRPV1 may provide pulpal analgesia [130, 132].
GABA	Dental pulp [11].	Dental pulp [12, 164]. TG [163].	No	<ul style="list-style-type: none"> - GABA-mediated inhibitory neurotransmission [11, 12, 158, 159]. - 5-HT mediated GABAergic inhibition [167, 168]. - Hyperalgesia reduction by GABA peripheral analgesic effects [165]. - Blood flow regulation through inhibition of noradrenaline release in dental pulp [160].
Neuropeptides				
Somatostatin	Dental pulp [10].	Dental pulp [212].	No	<ul style="list-style-type: none"> - Anti-inflammatory neuropeptide that down-modulates a number of immune functions [175, 193]. - Decreases the neurogenic inflammation [175, 193]. - Inhibits CGRP release from the trigeminal neurons [205]. - Exerts antinociceptive functions [179-182, 187, 188]. - Decreases the conductance of voltage-gated Ca²⁺ channels [172, 183] and activates K⁺ channels [184-186].
Cortistatin	Dental pulp [212].	N/A	No	<ul style="list-style-type: none"> - Potent anti-inflammatory effect [195, 204, 211] by regulating immune tolerance [2009]. - Deactivation of inflammatory responses [196, 203, 206, 207]. - Decreases the presence/activation of Th1 and Th17 cells in the periphery [211]. - Inhibits pro-inflammatory mediators (TNF, IL-6, IL-12, IL-1, NO, and GM-CSF) and increases the levels of IL-10 [208, 209].

(Table 1) contd.....

Potential Mechanism	Ligands Identified in the Dental Pulp or TG	Receptors Identified in the Dental Pulp or TG	Role Confirmed in AIP-related Analgesia	Potential Mechanisms Involved in the Painless Nature of AIP
				<ul style="list-style-type: none"> - Relieves hyperalgesia and allodynia and acts as a neuroprotector and neuroregenerator [205]. - Analgesic effect in inflammatory [197] and neuropathic pain [210]. - Inhibits the CGRP release from the trigeminal neurons [205]. - Depresses the neuronal electrical activity [206]. - Relieves hyperalgesia and allodynia and acts as a neuroprotector and neuroregenerator [205]. - Analgesic effect in inflammatory [197] and neuropathic pain [210]. - Inhibits the CGRP release from the trigeminal neurons [205]. - Depresses the neuronal electrical activity [206].
Galanin	Dental pulp [212]. TG [245].	Dental pulp [241]. TG [241, 245].	No	<ul style="list-style-type: none"> - Antinociceptive effect [225-235, 240]. - Opioid systems are involved in the galanin-induced antinociception [240].
Bombesin	Dental pulp [13]. TG [252].	N/A	No	<ul style="list-style-type: none"> - Antinociceptive effect [13]. - Depolarizes GABAergic interneurons at the presynaptic level and reduces the conductance of the neuronal membrane [250].
Specialized pro-resolving lipid mediators (SPMs)				
Lipoxins	N/A	N/A	No	- Potent pro-resolving and anti-inflammatory effects and analgesic action [264, 265].
Resolvins	N/A	N/A	No	<ul style="list-style-type: none"> - Potent pro-resolving and anti-inflammatory effects and analgesic action [264, 265]. - Analgesic effect in inflammatory pain [259, 260, 262, 269]. - Potent inhibition of TRP channels [261].
Maresins	N/A	N/A	No	- Potent pro-resolving and anti-inflammatory effects and analgesic action [264, 265].
Protectins	N/A	N/A	No	- Potent pro-resolving and anti-inflammatory effects and analgesic action [264, 265].
Miscellaneous mechanisms				
Antinociceptive bacteria	-	-	No	<ul style="list-style-type: none"> - <i>Porphyromonas gingivalis</i> LPS exerts antinociceptive effects via an increase in IL-10 levels [270]. - <i>Bifidobacterium</i> species, such as <i>B. dentium</i>, produce GABA [281-283].
Oxytocin	TG [290].	TG [290-292].	No	<ul style="list-style-type: none"> - Induces membrane hyperpolarization in pain-sensitive dorsal root ganglia neurons [287]. - Antinociceptive effect [287-290]. - Inhibits the activity of acid-sensing ion channels [293]. - Suppresses nociception of inflammatory pain via TRPV1-desensitization [297].
Phoenixin	TG [298].	Dental pulp [299].	No	- Suppresses the lipopolysaccharide-induced inflammation in dental pulp cells, suppressing the release of pro-inflammatory cytokines and inflammatory mediators [299].
Opiorphin	N/A	N/A	No	- Protects enkephalins from degradation and activates restricted opioid pathways specifically involved in pain control [300-303].
Adipokines	Dental pulp [304].	Dental pulp [304].	No	Some exert anti-inflammatory effects by inducing the secretion of anti-inflammatory interleukins or inhibiting the production of proinflammatory cytokines [304].

N/A: not available information.

CONCLUSION

This review presents up-to-date information on the painless nature of AIP. Factors that could potentially be involved in the mechanisms of analgesia underlying AIP include endogenous opioids, GIRK channels, endogenous cannabinoids, GABA, neuropeptides (somatostatin, cortistatin, galanin, and bombesin), and SPMs (lipoxins, resolvins, and maresins). We have also identified some miscellaneous factors that could play a role in AIP, such as bacteria with their antinociceptive effects, oxytocin, phoenixin, opiorphin, and adipokines, considering their potential analgesic-related mechanisms.

Nevertheless, the precise mechanisms responsible for the lack of symptoms in AIP remain to be elucidated, and further research is warranted despite the recent advances in

science and technology. The available literature mainly investigated symptomatic irreversible pulpitis (SIP), where a recent study determined the levels of inflammation, oxidative stress, and extracellular matrix degradation biomarkers in SIP [305, 306]. Thus, it is compelling to perform a similar biochemical mapping for AIP that helps elucidate the expression pattern of endogenous analgesic biomolecules. Furthermore, vascular, neural, cellular, and biochemical changes can occur without pain (8).

Moreover, it is important to highlight the chronic nature of AIP. In this regard, systemic chronic inflammation constitutes a health-damaging phenotype that is triggered by damage-associated molecular patterns, is persistent (non-resolving), has low-grade magnitude, leads to collateral damage, is age-related, and is silent (has no canonical standard biomarkers) [307]. The influence of these factors

should be investigated to collect data concerning the analgesic features and pathophysiology of AIP in the context of the local microenvironment of the pulp tissue.

Furthermore, multiplatform data-integration models have been used to identify the differentially expressed genes to analyze the molecular mechanisms underlying pulpitis [308, 309]. Thus, they could improve our current understanding of the nature of AIP. Genetic and epigenetic characterization of pulpal inflammation can also help decipher the balance between proinflammatory and anti-inflammatory gene expression in AIP [310] and how it influences analgesia. This is especially relevant as several genes known to modulate pain and inflammation show a higher level of differential expression in patients with asymptomatic and mild pain compared to those with moderate to severe pain [311].

Regarding the limitations of this review, it must be highlighted that most studies were performed on animals, and AIP could not be differentiated from SIP. Furthermore, our search was confined to two electronic databases, potentially limiting the inclusion of relevant literature in our review. Despite these limitations, our study possesses notable strengths. We have meticulously compiled a substantial amount of data, contributing to an updated narrative review that delves into the potential mechanisms behind the asymptomatic nature of AIP. Notably, the latest report on the fundamentals of the painless nature of AIP describes a clinical study that was performed two decades ago [16]. Additionally, our findings could offer valuable insights for designing new studies aimed at identifying the precise molecular mechanisms responsible for the absence of symptoms in AIP.

Although the present review enlists some candidate ligands and/or receptors that potentially regulate the asymptomatic nature of AIP, no direct evidence supports these statements (Table 1). Indeed, the literature regarding this topic is scarce. However, paradoxically, patients with dental diseases are diagnosed with AIP daily worldwide. Therefore, understanding the analgesia and biology behind AIP is necessary and could help improve the clinical diagnosis of pulp pathology, especially since recent investigations have shown a good correlation between the clinical symptoms of pulpitis and histological findings [312]. On the other hand, anecdotal reports among dentists confirm that in some AIP cases that may have had trauma or deep caries, the inflamed pulp tissue is open to the oral cavity. This would mean no or little increase in pulpal tissue pressure is induced, which is thought to be involved in the “asymptomatic” AIP condition. However, this assumption is very simplistic in explaining the potential biological fundamentals behind AIP.

Finally, other dental and medical pathologies share asymptomatic characteristics similar to those of AIP. These include symptomless pericoronitis [313, 314], chronic periodontitis [315], asymptomatic apical periodontitis [316-318], congenital painlessness disorders [319-321], painless neuropathies [322], *NGF* mutations [323], Buruli ulcer [324], and painless chronic pancreatitis [325-327]. Hence, analyzing the cellular, biochemical, and/or clinical findings from these conditions could help enhance our understanding of the possible mechanisms underlying the asymptomatic nature of AIP.

LIST OF ABBREVIATIONS

BN	= Bombesin
CBRs	= Cannabinoid Receptors
CORT	= Cortistatin
EOP	= Endogenous Opioid Peptides
FAAH	= Fatty Acid Amide Hydrolase
GABA	= Gamma-aminobutyric Acid
GAL	= Galanin
GIRK	= G Protein-activated Inwardly Rectifying K+ Channels
NADA	= N-arachidonoyl-dopamine
NOR	= Nociceptin/orphanin Receptor
OXT	= Oxytocin
OX1Rs	= Orexin 1 Receptors
SPMs	= Specialized Pro-resolving Lipid Mediators
SST	= Somatostatin
TRPV1	= Transient Receptor Potential Vanilloid Subtype 1 Channel
vIPAG	= Ventrolateral Periaqueductal Gray Matter
2-AG	= 2-arachidonylglycerol

AUTHORS' CONTRIBUTIONS

D.P.C., V.C.J. and J.L.A. contributed to literature search, writing-original draft preparation, writing-review, and editing. J.L.A. contributed to conceptualization, methodology, critical revision of the article, supervision and project administration. All authors have read and agreed to the published version of the manuscript.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The data and supportive information are available within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

This article is based on Daniela Paola Cabrera-Abad and Verónica Cristina Jara-Vergara undergraduate thesis.

The APC was supported by the Vice Chancellor's Office for Research of the University of Cuenca (VIUC).

REFERENCES

- [1] Yu C, Abbott PV. An overview of the dental pulp: its functions and responses to injury. *Aust Dent J* 2007; 52(1) (Suppl.): S4-S16. <http://dx.doi.org/10.1111/j.1834-7819.2007.tb00525>

- [2] Ravindran S, Huang CC, George A. Extracellular matrix of dental pulp stem cells: applications in pulp tissue engineering using somatic MSCs. *Front Physiol* 2014; 4: 395. <http://dx.doi.org/10.3389/fphys.2013.00395>
- [3] Galler KM, Weber M, Korkmaz Y, Widbiller M, Feuerer M. Inflammatory Response Mechanisms of the Dentine-Pulp Complex and the Periapical Tissues. *Int J Mol Sci* 2021; 22(3): 1480. <http://dx.doi.org/10.3390/ijms22031480>
- [4] Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of untreated caries: a systematic review and metaregression. *J Dent Res* 2015; 94(5): 650-8. <http://dx.doi.org/10.1177/0022034515573272>
- [5] Wang Y, Zhai S, Wang H, et al. Absent in Melanoma 2 (AIM2) in Rat Dental Pulp Mediates the Inflammatory Response during Pulpitis. *J Endod* 2013; 39(11): 1390-4. <http://dx.doi.org/10.1016/j.joen.2013.07.003>
- [6] Glickman GN. AAE Consensus Conference on Diagnostic Terminology: background and perspectives. *J Endod* 2009; 35(12): 1619-20. <http://dx.doi.org/10.1016/j.joen.2009.09.029>
- [7] Byers M, Henry M, Närhi M. Dental innervation and its responses to tooth injury. *Seltzer and Bender's Dental pulp*. US: Quintessence Publishing Co 2012; pp. 133-58.
- [8] Chavarría-Bolaños D, Flores-Reyes H, Lombana-Sanchez N, Cerda-Cristerna B, Pozos-Guillen A. Sensory neuropeptides and endogenous opioids expression in human dental pulp with asymptomatic inflammation: *in vivo* study. *Mediators Inflamm* 2015; 2015879126 <http://dx.doi.org/10.1155/2015/879126>
- [9] Jaber L, Swaim WD, Dionne RA. Immunohistochemical localization of mu-opioid receptors in human dental pulp. *J Endod* 2003; 29(2): 108-10. <http://dx.doi.org/10.1097/00004770-200302000-00005>
- [10] Casasco A, Calligaro A, Casasco M, et al. Peptidergic nerves in human dental pulp. An immunocytochemical study. *Histochemistry* 1990; 95(2): 115-21. <http://dx.doi.org/10.1007/bf00266583>
- [11] Mitirattanakul S, Poomsawat S, Fuangtharntip P. Cannabinoid receptor 1 (CB1R) expression in rat dental pulp. *Oral Sci Int* 2012; 9(1): 17-20. [http://dx.doi.org/10.1016/S1348-8643\(12\)00003-1](http://dx.doi.org/10.1016/S1348-8643(12)00003-1)
- [12] Beneng K, Renton T, Yilmaz Z, Yiangou Y, Anand P. Cannabinoid receptor CB1-immunoreactive nerve fibres in painful and non-painful human tooth pulp. *J Clin Neurosci* 2010; 17(11): 1476-9. <http://dx.doi.org/10.1016/j.jocn.2010.04.005>
- [13] Todd WM, Kafrawy AH, Newton CW, Brown CE. Immunohistochemical study of gamma-aminobutyric acid and bombesin/gastrin releasing peptide in human dental pulp. *J Endod* 1997; 23(3): 152-7. [http://dx.doi.org/10.1016/S0099-2399\(97\)80265-8](http://dx.doi.org/10.1016/S0099-2399(97)80265-8)
- [14] Wurm C, Richardson JD, Bowles W, Hargreaves KM. Evaluation of functional GABA(B) receptors in dental pulp. *J Endod* 2001; 27(10): 620-3. <http://dx.doi.org/10.1097/00004770-200110000-00005>
- [15] Mudie AS, Holland GR. Local Opioids in the Inflamed Dental Pulp. *J Endod* 2006; 32(4): 319-23. <http://dx.doi.org/10.1016/j.joen.2005.08.010>
- [16] Michaelson PL, Holland GR. Is pulpitis painful? *Int Endod J* 2002; 35(10): 829-32. <http://dx.doi.org/10.1046/j.1365-2591.2002.00579.x>
- [17] Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and Exogenous Opioids in Pain. *Annu Rev Neurosci* 2018; 4: 453-73. <http://dx.doi.org/10.1146/annurev-neuro-080317-061522>
- [18] Bentley GA, Newton SH, Starr J. Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum. *Br J Pharmacol* 1981; 73(2): 325-32. <http://dx.doi.org/10.1111/j.1476-5381.1981.tb10425.x>
- [19] Schultzberg M, Lundberg JM, Hökfelt T, et al. Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla. *Neuroscience* 1978; 3(12): 1169-86. [http://dx.doi.org/10.1016/0306-4522\(78\)90137-9](http://dx.doi.org/10.1016/0306-4522(78)90137-9)
- [20] Joris JL, Dubner R, Hargreaves KM. Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation? *Anesth Analg* 1987; 66(12): 1277-81.
- [21] Cabot PJ, Carter L, Gaiddon C, et al. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. *J Clin Invest* 1997; 100(1): 142-8. <http://dx.doi.org/10.1172/JCI119506>
- [22] Przewłocki R, Hassan AH, Lason W, Eppel C, Herz A, Stein C. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. *Neuroscience* 1992; 48(2): 491-500. [http://dx.doi.org/10.1016/0306-4522\(92\)90509-Z](http://dx.doi.org/10.1016/0306-4522(92)90509-Z)
- [23] Stein C, Hassan AH, Przewłocki R, Gramsch C, Peter K, Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci USA* 1990; 87(15): 5935-9. <http://dx.doi.org/10.1073/pnas.87.15.5935>
- [24] Mousa SA, Shakibaei M, Sitte N, Schäfer M, Stein C. Subcellular pathways of beta-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. *Endocrinology* 2004; 145(3): 1331-41. <http://dx.doi.org/10.1210/en.2003-1287>
- [25] Basbaum A, Kaneko A, Shepherd G, Westheimer G. *The Senses: A Comprehensive Reference*. (1st ed.), Amsterdam: Elsevier 2008.
- [26] Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. *Nat Med* 2003; 9(8): 1003-8. <http://dx.doi.org/10.1038/nm908>
- [27] Desiderio DM, Tanzer FS, Fridland G. Metabolic profiling of opioid peptides in tooth pulp by HPLC and radioreceptor assay. *Neuropeptides* 1985; 6(5): 463-9. [http://dx.doi.org/10.1016/0143-4179\(85\)90145-3](http://dx.doi.org/10.1016/0143-4179(85)90145-3)
- [28] Robinson QC, Killmar JT, Desiderio DM, Harris EF, Fridland G. Immunoreactive evidence of beta-endorphin and methionine-enkephalin-Arg-Gly-Leu in human tooth pulp. *Life Sci* 1989; 45(11): 987-92. [http://dx.doi.org/10.1016/0024-3205\(89\)90152-5](http://dx.doi.org/10.1016/0024-3205(89)90152-5)
- [29] Childers SR. Opioid receptor-coupled second messenger systems. *Life Sci* 1991; 48(21): 1991-2003. [http://dx.doi.org/10.1016/0024-3205\(91\)90154-4](http://dx.doi.org/10.1016/0024-3205(91)90154-4)
- [30] Antonijevic I, Mousa SA, Schäfer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. *J Neurosci* 1995; 15(1Pt1): 165-72. <http://dx.doi.org/10.1523/JNEUROSCI.15-01-00165.1995>
- [31] Barber A, Gottschlich R. Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. *Med Res Rev* 1992; 12(5): 525-62. <http://dx.doi.org/10.1002/med.2610120505>
- [32] Spetea M, Rydelius G, Nylander I, et al. Alteration in endogenous opioid systems due to chronic inflammatory pain conditions. *Eur J Pharmacol* 2002; 435(2): 245-52. [http://dx.doi.org/10.1016/S0014-2999\(01\)01554-0](http://dx.doi.org/10.1016/S0014-2999(01)01554-0)
- [33] Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. *FEBS Lett* 1994; 341(1): 33-8. [http://dx.doi.org/10.1016/0014-5793\(94\)80235-1](http://dx.doi.org/10.1016/0014-5793(94)80235-1)
- [34] Gao CJ, Niu L, Ren PC, et al. Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system. *Neuroscience* 2012; 202: 352-62. <http://dx.doi.org/10.1016/j.neuroscience.2011.11.060>
- [35] Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuroprotection in the retina. *Curr Pharm Des* 2012; 18(37): 6101-8. <http://dx.doi.org/10.2174/138161212803582441>
- [36] Maslov LN, Naryzhnaia NV, Tsubulnikov SY, et al. Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia. *Life Sci* 2013; 93(9-11): 373-9. <http://dx.doi.org/10.1016/j.lfs.2013.07.018>

- [37] Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current Research on Opioid Receptor Function. *Curr Drug Targets* 2012; 13(2): 230-46.
<http://dx.doi.org/10.2174/138945012799201612>
- [38] Rusin KI, Giovannucci DR, Stuenkel EL, Moises HC. Kappa-opioid receptor activation modulates Ca²⁺ currents and secretion in isolated neuroendocrine nerve terminals. *J Neurosci* 1997; 17(17): 6565-74.
<http://dx.doi.org/10.1523/JNEUROSCI.17-17-06565.1997>
- [39] Zöllner C, Stein C. Opioids. *Handb Exp Pharmacol* 2007; (177): 31-63.
http://dx.doi.org/10.1007/978-3-540-33823-9_2
- [40] Fristad I, Berggreen E, Haug SR. Delta (delta) opioid receptors in small and medium-sized trigeminal neurons supporting the dental pulp of rats. *Arch Oral Biol* 2006; 51(4): 273-81.
<http://dx.doi.org/10.1016/j.archoralbio.2005.08.007>
- [41] Rechthand E, Rapoport SI. Regulation of the microenvironment of peripheral nerve: role of the blood-nerve barrier. *Prog Neurobiol* 1987; 28(4): 303-43.
[http://dx.doi.org/10.1016/0301-0082\(87\)90006-2](http://dx.doi.org/10.1016/0301-0082(87)90006-2)
- [42] Olsson Y. Microenvironment of the peripheral nervous system under normal and pathological conditions. *Crit Rev Neurobiol* 1990; 5(3): 265-311.
- [43] Herz A. Peripheral opioid analgesia-facts and mechanisms. *Prog Brain Res* 1996; 110: 95-104.
[http://dx.doi.org/10.1016/S0079-6123\(08\)62567-4](http://dx.doi.org/10.1016/S0079-6123(08)62567-4)
- [44] Rittner HL, Amasheh S, Moshourab R, *et al.* Modulation of tight junction proteins in the perineurium to facilitate peripheral opioid analgesia. *Anesthesiology* 2012; 116(6): 1323-34.
<http://dx.doi.org/10.1097/ALN.0b013e318256e6eb>
- [45] Mousa SA, Zhang Q, Sitte N, Ji R, Stein C. Beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. *J Neuroimmunol* 2001; 115(1-2): 71-8.
[http://dx.doi.org/10.1016/S0165-5728\(01\)00271-5](http://dx.doi.org/10.1016/S0165-5728(01)00271-5)
- [46] Asvadi NH, Morgan M, Herath HM, Hewavitharana AK, Shaw PN, Cabot PJ. Beta-Endorphin 1-31 Biotransformation and cAMP Modulation in Inflammation. *PLoS One* 2014; 9(3):e90380.
<http://dx.doi.org/10.1371/journal.pone.0090380>
- [47] Brack A, Rittner HL, Machelska H, *et al.* Endogenous peripheral antinociception in early inflammation is not limited by the number of opioid-containing leukocytes but by opioid receptor expression. *Pain* 2004; 108(1-2): 67-75.
<http://dx.doi.org/10.1016/j.pain.2003.12.008>
- [48] Rittner HL, Brack A, Machelska H, *et al.* Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. *Anesthesiology* 2001; 95(2): 500-8.
<http://dx.doi.org/10.1097/00000542-200108000-00036>
- [49] Zollner C, Shaqura MA, Bopaiha CP, Mousa S, Stein C, Schafer M. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. *Mol Pharmacol* 2003; 64(2): 202-10.
<http://dx.doi.org/10.1124/mol.64.2.202>
- [50] Binder W, Mousa SA, Sitte N, Kaiser M, Stein C, Schäfer M. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. *Eur J Neurosci* 2004; 20(1): 92-100.
<http://dx.doi.org/10.1111/j.1460-9568.2004.03459.x>
- [51] Labuz D, Mousa SA, Schäfer M, Stein C, Machelska H. Relative contribution of peripheral versus central opioid receptors to antinociception. *Brain Res* 2007; 1160: 30-8.
<http://dx.doi.org/10.1016/j.brainres.2007.05.049>
- [52] Hua S, Cabot PJ. Mechanisms of peripheral immune-cell-mediated analgesia in inflammation: clinical and therapeutic implications. *Trends Pharmacol Sci* 2010; 31(9): 427-33.
<http://dx.doi.org/10.1016/j.tips.2010.05.008>
- [53] Machelska H, Schopohl JK, Mousa SA, Labuz D, Schäfer M, Stein C. Different mechanisms of intrinsic pain inhibition in early and late inflammation. *J Neuroimmunol* 2003; 141(1-2): 30-9.
[http://dx.doi.org/10.1016/S0165-5728\(03\)00213-3](http://dx.doi.org/10.1016/S0165-5728(03)00213-3)
- [54] Stein C, Gramsch C, Herz A. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. *J Neurosci* 1990; 10(4): 1292-8.
<http://dx.doi.org/10.1523/JNEUROSCI.10-04-01292.1990>
- [55] Busch-Dienstfertig M, Stein C. Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain -basic and therapeutic aspects. *Brain Behav Immun* 2010; 24(5): 683-94.
<http://dx.doi.org/10.1016/j.bbi.2009.10.013>
- [56] Labuz D, Berger S, Mousa SA, *et al.* Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. *J Neurosci* 2006; 26(16): 4350-8.
<http://dx.doi.org/10.1523/JNEUROSCI.4349-05.2006>
- [57] Byers MR, Chudler EH, Ladarola MJ. Chronic tooth pulp inflammation causes transient and persistent expression of Fos in dynorphin-rich regions of rat brainstem. *Brain Res* 2000; 861(2): 191-207.
[http://dx.doi.org/10.1016/S0006-8993\(00\)01936-3](http://dx.doi.org/10.1016/S0006-8993(00)01936-3)
- [58] Kudo T, Chang HL, Kuroi M, Wakisaka S, Akai M, Inoki R. Influences of bradykinin and substance P on the met-enkephalin-like peptide content in the rat incisor pulp. *Neuropeptides* 1986; 7(4): 399-405.
[http://dx.doi.org/10.1016/0143-4179\(86\)90033-8](http://dx.doi.org/10.1016/0143-4179(86)90033-8)
- [59] Parris WG, Tanzer FS, Fridland GH, Harris EF, Killmar J, Desiderio DM. Effects of orthodontic force on methionine enkephalin and substance P concentrations in human pulpal tissue. *Am J Orthod Dentofacial Orthop* 1989; 95(6): 479-89.
[http://dx.doi.org/10.1016/0889-5406\(89\)90411-3](http://dx.doi.org/10.1016/0889-5406(89)90411-3)
- [60] Inoki R, Kudo T. Enkephalins and bradykinin in dental pulp. *Trends Pharmacol Sci* 1986; 7: 275-7.
[http://dx.doi.org/10.1016/0165-6147\(86\)90351-2](http://dx.doi.org/10.1016/0165-6147(86)90351-2)
- [61] Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. Pain control in inflammation governed by selectins. *Nat Med* 1998; 4(12): 1425-8.
<http://dx.doi.org/10.1038/4017>
- [62] Sattari M, Mozayeni MA, Matloob A, Mozayeni M, Javaheri HH. Substance P and CGRP expression in dental pulps with irreversible pulpitis. *Aust Endod J* 2010; 36(2): 59-63.
<http://dx.doi.org/10.1111/j.1747-4477.2009.00186.x>
- [63] Parenti C, Aricò G, Ronsisvalle G, Scoto GM. Supraspinal injection of substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain. *Peptides* 2012; 34(2): 412-8.
<http://dx.doi.org/10.1016/j.peptides.2012.01.016>
- [64] Lundy FT, Linden CJ. Neuropeptides and neurogenic mechanisms in oral and periodontal inflammation. *Crit Rev Oral Biol Med* 2004; 15(2): 82-98.
<http://dx.doi.org/10.1177/154411130401500203>
- [65] Celik MÖ, Labuz D, Keye J, Glauben R, Machelska H. IL-4 induces M2 macrophages to produce sustained analgesia via opioids. *JCI Insight* 2020; 5(4):133093
<http://dx.doi.org/10.1172/jci.insight.133093>
- [66] Rutz JC, Hatton JF, Hildebolt C, Wells JE, Rowland KC. Localized increases in corticotropin-releasing factor receptors in pulp after dental injury. *J Endod* 2007; 33(11): 1319-24.
<http://dx.doi.org/10.1016/j.joen.2007.08.009>
- [67] Smith EM, Morrill AC, Meyer WJ, Blalock JE. Corticotropin releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins. *Nature* 1986; 321(6073): 881-2.
<http://dx.doi.org/10.1038/321881a0>
- [68] Cabot PJ, Carter L, Schäfer M, Stein C. Methionine-enkephalin and Dynorphin A-release from immune cells and control of inflammatory pain. *Pain* 2001; 93(3): 207-12.
[http://dx.doi.org/10.1016/S0304-3959\(01\)00322-0](http://dx.doi.org/10.1016/S0304-3959(01)00322-0)
- [69] Schäfer M, Carter L, Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. *Proc Natl Acad Sci USA* 1994; 91(10): 4219-23.
<http://dx.doi.org/10.1073/pnas.91.10.421>
- [70] Kavelaars A, Berkenbosch F, Croiset G, Ballieux RE, Heijnen CJ. Induction of beta-endorphin secretion by lymphocytes after

- subcutaneous administration of corticotropin-releasing factor. *Endocrinology* 1990; 126(2): 759-64.
<http://dx.doi.org/10.1210/endo-126-2-759>
- [71] Mousa SA, Bopaiah PC, Stein C, Schäfer M. Involvement of corticotropin-releasing hormone receptor subtypes 1 and 2 in peripheral opioid-mediated inhibition of inflammatory pain. *Pain* 2003; 106(3): 297-307.
[http://dx.doi.org/10.1016/s0304-3959\(03\)00302-6](http://dx.doi.org/10.1016/s0304-3959(03)00302-6)
- [72] Rittner HL, Labuz D, Schaefer M, et al. Pain control by CXCR2 ligands through Ca²⁺-regulated release of opioid peptides from polymorphonuclear cells. *FASEB J* 2006; 20(14): 2627-9.
<http://dx.doi.org/10.1096/fj.06-6077fj>
- [73] Mousa SA, Schäfer M, Mitchell WM, Hassan AH, Stein C. Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. *Eur J Pharmacol* 1996; 311(2-3): 221-31.
[http://dx.doi.org/10.1016/0014-2999\(96\)00440-2](http://dx.doi.org/10.1016/0014-2999(96)00440-2)
- [74] Gavalas A, Victoratos P, Yiangou M, Hadjipetrou-Kourounakis L, Rekkas E, Kourounakis P. The anti-inflammatory effect of opioids. *Int J Neurosci* 1994; 74(1-4): 259-64.
<http://dx.doi.org/10.3109/00207459408987244>
- [75] Van der Vlist M, Raouf R, Willemsen HJLM, et al. Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain. *Neuron* 2022; 110(4): 613-626.e9.
<http://dx.doi.org/10.1016/j.neuron.2021.11.020>
- [76] Gao L, Fan F, Wang L, et al. Polarization of macrophages in the trigeminal ganglion of rats with pulpitis. *J Oral Rehabil* 2022; 49(2): 228-36.
<http://dx.doi.org/10.1111/joor.13245>
- [77] Da Silva MD, Bobinski F, Sato KL, Kolker SJ, Sluka KA, Santos ARS. IL-10 cytokine released from M2 macrophages is crucial for analgesic and anti-inflammatory effects of acupuncture in a model of inflammatory muscle pain. *Mol Neurobiol* 2015; 51(1): 19-31.
<http://dx.doi.org/10.1007/s12035-014-8790-x>
- [78] Vale ML, Marques JB, Moreira CA, et al. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. *J Pharmacol Exp Ther* 2003; 304(1): 102-8.
<http://dx.doi.org/10.1124/jpet.102.038703>
- [79] Vanderwall AG, Milligan ED. Cytokines in pain: Harnessing endogenous anti-inflammatory signaling for improved pain management. *Front Immunol* 2019; 10: 3009.
<http://dx.doi.org/10.3389/fimmu.2019.03009>
- [80] Kavelaars A, Heijnen CJ. T cells as guardians of pain resolution. *Trends Mol Med* 2021; 27(4): 302-13.
<http://dx.doi.org/10.1016/j.molmed.2020.12.007>
- [81] Ledebor A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. *Brain Behav Immun* 2007; 21(5): 686-98.
<http://dx.doi.org/10.1016/j.bbi.2006.10.012>
- [82] Shen KF, Zhu HQ, Wei XH, et al. Interleukin-10 down-regulates voltage gated sodium channels in rat dorsal root ganglion neurons. *Exp Neurol* 2013; 247: 466-75.
<http://dx.doi.org/10.1016/j.expneurol.2013.01.018>
- [83] Kimura M, Shiokawa H, Karashima Y, Sumie M, Hoka S, Yamaura K. Antinociceptive effect of selective G protein-gated inwardly rectifying K⁺ channel agonist ML297 in the rat spinal cord. *PLoS One* 2020; 15(9): e0239094.
<http://dx.doi.org/10.1371/journal.pone.0239094>
- [84] Gao XF, Zhang HL, You ZD, Lu CL, He C. G protein-coupled inwardly rectifying potassium channels in dorsal root ganglion neurons. *Acta Pharmacol Sin* 2007; 28(2): 185-90.
<http://dx.doi.org/10.1111/j.1745-7254.2007.00478.x>
- [85] Nockemann D, Rouault M, Labuz D, et al. The K(+) channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia. *EMBO Mol Med* 2013; 5(8): 1263-77.
<http://dx.doi.org/10.1002/emmm.201201980>
- [86] Karschin C, Dissmann E, Stühmer W, Karschin A. IRK(1-3) and GIRK(1-4) inwardly rectifying K⁺ channel mRNAs are differentially expressed in the adult rat brain. *J Neurosci* 1996; 16(11): 3559-70.
<http://dx.doi.org/10.1523/JNEUROSCI.16-11-03559.1996>
- [87] Lüscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. *Nat Rev Neurosci* 2010; 11(5): 301-15.
<http://dx.doi.org/10.1038/nrn2834>
- [88] Marker CL, Stoffel M, Wickman K. Spinal G-protein-gated K⁺ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. *J Neurosci* 2004; 24(11): 2806-12.
<http://dx.doi.org/10.1523/JNEUROSCI.5251-03.2004>
- [89] Blednov YA, Stoffel M, Alva H, Harris RA. A pervasive mechanism for analgesia: activation of GIRK2 channels. *Proc Natl Acad Sci USA* 2003; 100(1): 277-82.
<http://dx.doi.org/10.1073/pnas.012682399>
- [90] Nagi K, Pineyro G. Kir3 channel signaling complexes: focus on opioid receptor signaling. *Front Cell Neurosci* 2014; 8: 186.
<http://dx.doi.org/10.3389/fncel.2014.00186>
- [91] Smith KE, Walker MW, Artyushyn R, et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K⁺ channels. *J Biol Chem* 1998; 273(36): 23321-6.
<http://dx.doi.org/10.1074/jbc.273.36.23321>
- [92] Dahlhaus A, Ruscheweyh R, Sandkühler J. Synaptic input of rat spinal lamina I projection and unidentified neurones in vitro. *J Physiol* 2005; 566(Pt2): 355-68.
<http://dx.doi.org/10.1113/jphysiol.2005.088567>
- [93] Melnick IV. Cell type-specific postsynaptic effects of neuropeptide Y in substantia gelatinosa neurons of the rat spinal cord. *Synapse* 2012; 66(7): 640-9.
<http://dx.doi.org/10.1002/syn.21550>
- [94] Gorham L, Just S, Doods H. Somatostatin 4 receptor activation modulates G-protein coupled inward rectifying potassium channels and voltage stimulated calcium signals in dorsal root ganglion neurons. *Eur J Pharmacol* 2014; 736: 101-6.
<http://dx.doi.org/10.1016/j.ejphar.2014.04.016>
- [95] Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S. Superagonism at the human somatostatin receptor subtype 4. *J Pharmacol Exp Ther* 2005; 312(1): 332-8.
<http://dx.doi.org/10.1124/jpet.104.075531>
- [96] Chung MK, Cho YS, Bae YC, Lee J, Zhang X, Ro JY. Peripheral G protein-coupled inwardly rectifying potassium channels are involved in δ -opioid receptor-mediated anti-hyperalgesia in rat masseter muscle. *Eur J Pain* 2014; 18(1): 29-38.
<http://dx.doi.org/10.1002/j.1532-2149.2013.00343.x>
- [97] Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci* 2004; 74(11): 1317-24.
<http://dx.doi.org/10.1016/j.lfs.2003.09.038>
- [98] Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. *Curr Opin Pharmacol* 2010; 10(1): 80-6.
<http://dx.doi.org/10.1016/j.coph.2009.09.009>
- [99] Wilson-Poe AR, Pocius E, Herschbach M, Morgan MM. The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids. *Pharmacol Biochem Behav* 2013; 103(3): 444-9.
<http://dx.doi.org/10.1016/j.pbb.2012.10.002>
- [100] Tham SM, Angus JA, Tudor EM, Wright CE. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. *Br J Pharmacol* 2005; 144(6): 875-84.
<http://dx.doi.org/10.1038/sj.bjp.0706045>
- [101] Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *Eur J Pharmacol* 2006; 530(1-2): 54-8.
<http://dx.doi.org/10.1016/j.ejphar.2005.11.036>
- [102] Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. *Nature* 1998; 394(6690):

- 277-81.
<http://dx.doi.org/10.1038/28393>
- [103] Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. *Proc Natl Acad Sci USA* 1999; 96(21): 12198-203.
<http://dx.doi.org/10.1073/pnas.96.21.121>
- [104] Cravatt BF, Demarest K, Patricelli MP, *et al.* Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci USA* 2001; 98(16): 9371-6.
<http://dx.doi.org/10.1073/pnas.161191698>
- [105] Zubrzycki M, Janecka A, Liebold A, Ziegler M, Zubrzycka M. Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats. *Br J Pharmacol* 2017; 174(21): 3780-9.
<http://dx.doi.org/10.1111/bph.13970>
- [106] Guo J, Ikeda SR. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. *Mol Pharmacol* 2004; 65(3): 665-74.
<http://dx.doi.org/10.1124/mol.65.3.665>
- [107] Klein TW, Newton C, Larsen K, *et al.* The cannabinoid system and immune modulation. *J Leukoc Biol* 2003; 74(4): 486-96.
<http://dx.doi.org/10.1189/jlb.0303101>
- [108] Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. *Nat Rev Neurol* 2020; 16(1): 9-29.
<http://dx.doi.org/10.1038/s41582-019-0284-z>
- [109] Guindon J, Hohmann AG. The endocannabinoid system and pain. *CNS Neurol Disord Drug Targets* 2009; 8(6): 403-21.
<http://dx.doi.org/10.2174/2152709789824660>
- [110] Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. *Neuroscience* 2003; 120(4): 1157-70.
[http://dx.doi.org/10.1016/S0306-4522\(03\)00356-7](http://dx.doi.org/10.1016/S0306-4522(03)00356-7)
- [111] Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. *J Pharmacol Exp Ther* 1996; 276(2): 585-93.
- [112] Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. *Neurosci Lett* 1998; 242(1): 33-6.
[http://dx.doi.org/10.1016/S0304-3940\(98\)00044-5](http://dx.doi.org/10.1016/S0304-3940(98)00044-5)
- [113] Maccarrone M, De Petrocellis L, Bari M, *et al.* Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. *Arch Biochem Biophys* 2001; 393(2): 321-8.
<http://dx.doi.org/10.1006/abbi.2001.2500>
- [114] Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. *FASEB J* 1998; 12(11): 1035-44.
<http://dx.doi.org/10.1096/fasebj.12.11.1035>
- [115] Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990; 346(6284): 561-4.
<http://dx.doi.org/10.1038/346561a0>
- [116] Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 1993; 365(6441): 61-5.
<http://dx.doi.org/10.1038/365061a0>
- [117] Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 1988; 34(5): 605-13.
- [118] Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. *J Neurobiol* 2004; 61(1): 149-60.
<http://dx.doi.org/10.1002/neu.20080>
- [119] Howlett AC, Barth F, Bonner TI, *et al.* International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 2002; 54(2): 161-202.
<http://dx.doi.org/10.1124/pr.54.2.161>
- [120] Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: An overview. *Immunobiology* 2010; 215(8): 588-97.
<http://dx.doi.org/10.1016/j.imbio.2009.12.005>
- [121] Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. *J Biol Chem* 1997; 272(6): 3315-23.
<http://dx.doi.org/10.1074/jbc.272.6.3315>
- [122] Raouf M, Sofiabadi M, Haghdoost-Yazdi H, Kooshki R, Abbasnejad M. Blockage of ventrolateral periaqueductal gray matter cannabinoid 1 receptor increases dental pulp pain and pain-related subsequent learning and memory deficits in rats. *Behav Pharmacol* 2022; 33(2&3): 165-74.
<http://dx.doi.org/10.1097/fbp.0000000000000566>
- [123] Ho YC, Lee HJ, Tung LW, *et al.* Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-Arachidonoylglycerol)-induced disinhibition. *J Neurosci* 2011; 31(41): 14600-10.
<http://dx.doi.org/10.1523/JNEUROSCI.2671-11.2011>
- [124] Liao HT, Lee HJ, Ho YC, Chiou LC. Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition. *Br J Pharmacol* 2011; 163(2): 330-45.
<http://dx.doi.org/10.1111/j.1476-5381.2011.01214.x>
- [125] Behbehani MM, Jiang M, Chandler SD, Ennis M. The effect of GABA and its antagonists on midbrain periaqueductal gray neurons in the rat. *Pain* 1990; 40(2): 195-204.
[http://dx.doi.org/10.1016/0304-3959\(90\)90070-t](http://dx.doi.org/10.1016/0304-3959(90)90070-t)
- [126] Felder CC, Joyce KE, Briley EM, *et al.* Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol Pharmacol* 1995; 48(3): 443-50.
- [127] Ibsen MS, Connor M, Glass M. Cannabinoid CB1 and CB2 receptor signaling and bias. *Cannabis Cannabinoid Res* 2017; 2(1): 48-60.
<http://dx.doi.org/10.1089/can.2016.0037>
- [128] Ross HR, Gilmore AJ, Connor M. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. *Br J Pharmacol* 2009; 156(5): 740-50.
<http://dx.doi.org/10.1111/j.1476-5381.2008.00072.x>
- [129] O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. *Immunobiology* 2010; 215(8): 611-6.
<http://dx.doi.org/10.1016/j.imbio.2009.09.007>
- [130] Miyashita K, Oyama T, Sakuta T, Tokuda M, Torii M. Anandamide induces matrix metalloproteinase-2 production through cannabinoid-1 receptor and transient receptor potential vanilloid-1 in human dental pulp cells in culture. *J Endod* 2012; 38(6): 786-90.
<http://dx.doi.org/10.1016/j.joen.2012.02.025>
- [131] Kissin I, Szallasi A. Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. *Curr Top Med Chem* 2011; 11(17): 2159-70.
<http://dx.doi.org/10.2174/156802611796904924>
- [132] Engel MA, Izydorczyk I, Mueller-Tribensee SM, Becker C, Neurath MF, Reeh PW. Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. *Neuropeptides* 2011; 45(3): 229-37.
<http://dx.doi.org/10.1016/j.npep.2011.03.005>
- [133] Maione S, Bisogno T, De Novellis V, *et al.* Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. *J Pharmacol Exp Ther* 2006; 316(3): 969-82.
<http://dx.doi.org/10.1124/jpet.105.093286>
- [134] Palazzo E, Luongo L, De Novellis V, Berrino L, Rossi F, Maione S. Moving towards supraspinal TRPV1 receptors for chronic pain relief. *Mol Pain* 2010; 6: 66.
<http://dx.doi.org/10.1186/1744-8069-6-66>

- [135] McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. *Am J Ther* 2007; 14(5): 475-83. <http://dx.doi.org/10.1097/mjt.0b013e3180a5e581>
- [136] Mbvundula EC, Rainsford KD, Bunning RAD. Cannabinoids in pain and inflammation. *Inflammopharmacology* 2004; 12(2): 99-114. <http://dx.doi.org/10.1163/1568560041352275>
- [137] Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. Cannabinoids Desensitize Capsaicin and Mustard Oil Responses in Sensory Neurons via TRPA1 Activation. *J Neurosci* 2008; 28(5): 1064-75. <http://dx.doi.org/10.1523/JNEUROSCI.1565-06.2008>
- [138] Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyldopamine and arachidonyl-2-chloroethylamide. *Br J Pharmacol* 2004; 141(7): 1118-1130. <http://dx.doi.org/10.1038/sj.bjp.0705711>
- [139] Jordt SE, Bautista DM, Chuang HH, *et al.* Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. *Nature* 2004; 427(6971): 260-5. <http://dx.doi.org/10.1038/nature02282>
- [140] Liu L, Lo Y, Chen I, Simon SA. The responses of rat trigeminal ganglion neurons to capsaicin and two nonpungent vanilloid receptor agonists, olvanil and glyceryl nonamide. *J Neurosci* 1997; 17(11): 4101-11. <http://dx.doi.org/10.1523/JNEUROSCI.17-11-04101.1997>
- [141] Tsumura M, Sobhan U, Muramatsu T, *et al.* TRPV1-mediated calcium signal couples with cannabinoid receptors and sodium-calcium exchangers in rat odontoblasts. *Cell Calcium* 2012; 52(2): 124-36. <http://dx.doi.org/10.1016/j.ceca.2012.05.002>
- [142] Que K, He D, Jin Y, *et al.* Expression of Cannabinoid Type 1 Receptors in Human Odontoblast Cells. *J Endod* 2017; 43(2): 283-8. <http://dx.doi.org/10.1016/j.joen.2016.10.004>
- [143] Nikolaeva EP, Cox TC, Flake NM. Osseous characteristics of mice lacking cannabinoid receptor 2 after pulp exposure. *J Endod* 2015; 41(6): 853-7. <http://dx.doi.org/10.1016/j.joen.2015.01.030>
- [144] McPartland JM. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. *J Bodyw Mov Ther* 2008; 12(2): 169-82. <http://dx.doi.org/10.1016/j.jbmt.2008.01.004>
- [145] Qi X, Liu C, Li G, *et al.* Evaluation of cannabinoids on the odonto/osteogenesis in human dental pulp cells *in vitro*. *J Endod* 2021; 47(3): 444-50. <http://dx.doi.org/10.1016/j.joen.2020.12.005>
- [146] Matias I, Gonthier MP, Orlando P, *et al.* Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. *J Clin Endocrinol Metab* 2006; 91(8): 3171-80. <http://dx.doi.org/10.1210/jc.2005-2679>
- [147] Richardson D, Pearson RG, Kurian N, *et al.* Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther* 2008; 10(2): R43. <http://dx.doi.org/10.1186/ar2401>
- [148] McPartland JM, Skinner E. The biodynamic model of osteopathy in the cranial field. *Explore (NY)* 2005; 1(1): 21-32. <http://dx.doi.org/10.1016/j.explore.2004.10.005>
- [149] Flake NM, Zweifel LS. Behavioral Effects of Pulp Exposure in Mice Lacking Cannabinoid Receptor 2. *J Endod* 2012; 38(1): 86-90. <http://dx.doi.org/10.1016/j.joen.2011.09.015>
- [150] Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. *Br J Pharmacol* 2008; 153(2): 319-34. <http://dx.doi.org/10.1038/sj.bjp.0707531>
- [151] Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. *Cell Mol Life Sci* 2016; 73(23): 4449-70. <http://dx.doi.org/10.1007/s00018-016-2300-4>
- [152] Tang Y, Wolk B, Britch SC, Craft RM, Kendall DA. Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB2 receptor agonist ABK5. *J Pharmacol Sci* 2021; 145(4): 319-26. <http://dx.doi.org/10.1016/j.jphs.2020.12.006>
- [153] Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. *Br J Pharmacol* 2005; 145(4): 441-8. <http://dx.doi.org/10.1038/sj.bjp.0706215>
- [154] Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J Neuroimmunol* 2002; 133(1-2): 124-31. [http://dx.doi.org/10.1016/S0165-5728\(02\)00370-3](http://dx.doi.org/10.1016/S0165-5728(02)00370-3)
- [155] Börner C, Bedini A, Höllt V, Kraus J. Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. *Mol Pharmacol* 2008; 73(3): 1013-9. <http://dx.doi.org/10.1124/mol.107.042945>
- [156] Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines, cannabinoids and the nervous system. *Immunobiology* 2010; 215(8): 606-10. <http://dx.doi.org/10.1016/j.imbio.2009.12.006>
- [157] Crowley T, Cryan JF, Downer EJ, O'Leary OF. Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions. *Brain Behav Immun* 2016; 54: 260-77. <http://dx.doi.org/10.1016/j.bbi.2016.02.001>
- [158] Beltrán González AN, López Pazos MI, Calvo DJ. Reactive oxygen species in the regulation of the GABA mediated inhibitory neurotransmission. *Neuroscience* 2020; 439: 137-45. <http://dx.doi.org/10.1016/j.neuroscience.2019.05.064>
- [159] Goudet C, Magnaghi V, Landry M, Nagy F, Gereau R, Pin J. Metabotropic receptors for glutamate and GABA in pain. *Brain Res Brain Res Rev* 2009; 60(1): 43-56. <http://dx.doi.org/10.1016/j.brainresrev.2008.12.007>
- [160] Parker DAS, Marino V. GABA heteroreceptors modulate noradrenaline release in human dental pulp. *J Dent Res* 2013; 92(11): 1017-21. <http://dx.doi.org/10.1177/0022034513505771>
- [161] Wu LA, Huang J, Wang W, *et al.* Activation of GABAergic neurons following tooth pulp stimulation. *J Dent Res* 2010; 89(5): 532-6. <http://dx.doi.org/10.1177/0022034510363231>
- [162] Takeda M, Tanimoto T, Ikeda M, Kadoi J, Matsumoto S. Activation of GABA_B receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons. *Neuroscience* 2004; 123(2): 491-505. <http://dx.doi.org/10.1016/j.neuroscience.2003.09.022>
- [163] Ranjbar Ekbatan M, Cairns BE. Attenuation of sensory transmission through the rat trigeminal ganglion by GABA receptor activation. *Neuroscience* 2021; 471: 80-92. <http://dx.doi.org/10.1016/j.neuroscience.2021.07.018>
- [164] Nassery K, Marino V, Parker DAS. Uptake and release of [³H]GABA in human dental pulp. *Arch Oral Biol* 2007; 52(7): 607-13. <http://dx.doi.org/10.1016/j.archoralbio.2006.12.005>
- [165] Nowak P, Kowalińska-Kania M, Nowak D, Kostrzewa RM, Malinowska-Borowska J. Antinociceptive effects of H₃ (R-methylhistamine) and GABA(B) (baclofen)-receptor ligands in an orofacial model of pain in rats. *Neurotox Res* 2013; 24(2): 258-64. <http://dx.doi.org/10.1007/s12640-013-9385-4>
- [166] Whitehead RA, Puil E, Ries CR, *et al.* GABA(B) receptor-mediated selective peripheral analgesia by the non-proteinogenic amino acid, isovaline. *Neuroscience* 2012; 213: 154-60. <http://dx.doi.org/10.1016/j.neuroscience.2012.04.026>
- [167] Oshima K, Takeda M, Tanimoto T, Katsuumi I, Matsumoto S.

- Tooth-pulp-evoked rostral spinal trigeminal neuronal excitation is attenuated by the activation of 5-HT₃ receptors via GABAergic interneurons in the rat. *Brain Res* 2006; 1109(1): 70-3.
<http://dx.doi.org/10.1016/j.brainres.2006.06.036>
- [168] Oshima K, Takeda M, Tanimoto T, Katsuumi I, Matsumoto S. Tooth-pulp-evoked rostral spinal trigeminal nucleus neuron activity is inhibited by conditioning sciatic nerve stimulation in the rat: possible role of 5-HT₃ receptor mediated GABAergic inhibition. *Brain Res Bull* 2005; 65(1): 31-40.
<http://dx.doi.org/10.1016/j.brainresbull.2004.11.006>
- [169] Caviedes-Bucheli J, Muñoz HR, Azuero-Holguín MM, Ulate E. Neuropeptides in dental pulp: the silent protagonists. *J Endod* 2008; 34(7): 773-88.
<http://dx.doi.org/10.1016/j.joen.2008.03.010>
- [170] Abrams GM, Recht L. Neuropeptides and their role in pain and analgesia. *Acupunct Electrother Res* 1982; 7(2-3): 105-21.
<http://dx.doi.org/10.3727/036012982816952071>
- [171] Gamse R, Leeman SE, Holzer P, Lembeck F. Differential effects of capsaicin on the content of somatostatin, substance P, and neurotensin in the nervous system of the rat. *Naunyn Schmiedeberg's Arch Pharmacol* 1981; 317(2): 140-8.
<http://dx.doi.org/10.1007/BF00500070>
- [172] Patel YC. Somatostatin and its receptor family. *Front Neuroendocrinol* 1999; 20(3): 157-98.
<http://dx.doi.org/10.1006/frne.1999.0183>
- [173] Schuelert N, Just S, Kuelzer R, Corradini L, Gorham LCJ, Doods H. The somatostatin receptor 4 agonist J-2156 reduces mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model. *Eur J Pharmacol* 2015; 746: 274-81.
<http://dx.doi.org/10.1016/j.ejphar.2014.11.003>
- [174] Hökfelt T, Elde R, Johansson O, Luft R, Nilsson G, Arimura A. Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat. *Neuroscience* 1976; 1(2): 131-6.
[http://dx.doi.org/10.1016/0306-4522\(76\)90008-7](http://dx.doi.org/10.1016/0306-4522(76)90008-7)
- [175] Pintér E, Helyes Z, Szolcsányi J. Inhibitory effect of somatostatin on inflammation and nociception. *Pharmacol Ther* 2006; 112(2): 440-56.
<http://dx.doi.org/10.1016/j.pharmthera.2006.04.010>
- [176] Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. *Life Sci* 1995; 57(13): 1249-65.
[http://dx.doi.org/10.1016/0024-3205\(95\)02082-T](http://dx.doi.org/10.1016/0024-3205(95)02082-T)
- [177] Song YH, Yoon J, Lee SH. The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. *Exp Mol Med* 2021; 53(3): 328-38.
<http://dx.doi.org/10.1038/s12276-021-00580-4>
- [178] Hoyer D, Pérez J, Schoeffter P, et al. Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors. *Eur J Pharmacol* 1995; 289(1): 151-61.
[http://dx.doi.org/10.1016/0922-4106\(95\)90179-5](http://dx.doi.org/10.1016/0922-4106(95)90179-5)
- [179] Green PG, Basbaum AI, Levine JD. Sensory neuropeptide interactions in the production of plasma extravasation in the rat. *Neuroscience* 1992; 50(3): 745-9.
[http://dx.doi.org/10.1016/0306-4522\(92\)90461-A](http://dx.doi.org/10.1016/0306-4522(92)90461-A)
- [180] Morton CR, Hutchison WD, Hendry IA, Duggan AW. Somatostatin: evidence for a role in thermal nociception. *Brain Res* 1989; 488(1-2): 89-96.
[http://dx.doi.org/10.1016/0006-8993\(89\)90696-3](http://dx.doi.org/10.1016/0006-8993(89)90696-3)
- [181] Szolcsányi J, Bölcskei K, Szabó A, et al. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. *Eur J Pharmacol* 2004; 498(1-3): 103-9.
<http://dx.doi.org/10.1016/j.ejphar.2004.07.085>
- [182] Szolcsányi J, Pintér E, Helyes Z, Oroszi G, Németh J. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. *Br J Pharmacol* 1998; 125(4): 916-22.
<http://dx.doi.org/10.1038/sj.bjp.0702144>
- [183] Jian K, Barhoumi R, Ko ML, Ko GY. Inhibitory effect of somatostatin-14 on L-type voltage-gated calcium channels in cultured cone photoreceptors requires intracellular calcium. *J Neurophysiol* 2009; 102(3): 1801-10.
<http://dx.doi.org/10.1152/jn.00354.2009>
- [184] Mihara S, North RA, Surprenant A. Somatostatin increases an inwardly rectifying potassium conductance in guinea-pig submucous plexus neurones. *J Physiol* 1987; 390: 335-55.
<http://dx.doi.org/10.1113/jphysiol.1987.sp016704>
- [185] Moore SD, Madamba SG, Joëls M, Siggins GR. Somatostatin augments the M-current in hippocampal neurons. *Science* 1988; 239(4837): 278-80.
<http://dx.doi.org/10.1126/science.2892268>
- [186] Wang HL, Bogen C, Reisine T, Dichter M. Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. *Proc Natl Acad Sci USA* 1989; 86(23): 9616-20.
<http://dx.doi.org/10.1073/pnas.86.23.9616>
- [187] Toossi H, Del Cid-Pellitero E, Stroth T, Jones BE. Somatostatin varicosities contain the vesicular GABA transporter and contact orexin neurons in the hypothalamus. *Eur J Neurosci* 2012; 36(10): 3388-95.
<http://dx.doi.org/10.1111/j.1460-9568.2012.08253.x>
- [188] Randić M, Miletić V. Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli. *Brain Res* 1978; 152(1): 196-202.
[http://dx.doi.org/10.1016/0006-8993\(78\)90148-8](http://dx.doi.org/10.1016/0006-8993(78)90148-8)
- [189] Sicuteri F, Rainò L, Geppetti P. Substance P and endogenous opioids: how and where they could play a role in cluster headache. *Cephalalgia Int J Headache* 1983; 3 (Suppl. 1): 143-5.
<http://dx.doi.org/10.1177/03331024830030S122>
- [190] Scicchitano R, Dazin P, Bienenstock J, Payan DG, Stanis AM. The murine IgA-secreting plasmacytoma MOPC-315 expresses somatostatin receptors. *J Immunol* 1988; 141(3): 937-41.
- [191] Casasco A, Calligaro A, Casasco M, Springall DR, Polak JM, Marchetti C. Immunocytochemical Evidence for the Presence of Somatostatin-like Immunoreactive Nerves in Human Dental Pulp. *J Dent Res* 1991; 70(2): 87-9.
<http://dx.doi.org/10.1177/0022034591070002160>
- [192] Selmer I, Schindler M, Allen JP, Humphrey PP, Emson PC. Advances in understanding neuronal somatostatin receptors. *Regul Pept* 2000; 90(1-3): 1-18.
[http://dx.doi.org/10.1016/S0167-0115\(00\)00108-7](http://dx.doi.org/10.1016/S0167-0115(00)00108-7)
- [193] ten Bokum AM, Hofland LJ, van Hagen PM. Somatostatin and somatostatin receptors in the immune system: a review. *Eur Cytokine Netw* 2000; 11(2): 161-76.
- [194] Lawson SN. Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. *Prog Brain Res* 1995; 104: 161-73.
[http://dx.doi.org/10.1016/S0079-6123\(08\)61790-2](http://dx.doi.org/10.1016/S0079-6123(08)61790-2)
- [195] Gonzalez-Rey E, Varela N, Shebanie AF, Chorny A, Ganea D, Delgado M. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. *Proc Natl Acad Sci USA* 2006; 103(11): 4228-33.
<http://dx.doi.org/10.1073/pnas.0508997103>
- [196] Spier AD, de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. *Brain Res Brain Res Rev* 2000; 33(2-3): 228-41.
[http://dx.doi.org/10.1016/S0165-0173\(00\)00031-X](http://dx.doi.org/10.1016/S0165-0173(00)00031-X)
- [197] Morell M, Camprubi-Robles M, Culler MD, de Lecea L, Delgado M. Cortistatin attenuates inflammatory pain via spinal and peripheral actions. *Neurobiol Dis* 2014; 63: 141-54.
<http://dx.doi.org/10.1016/j.nbd.2013.11.022>
- [198] Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. *J Biol Chem* 2003; 278(45): 44400-4.
<http://dx.doi.org/10.1074/jbc.M302456200>
- [199] Flood JF, Uezu K, Morley JE. The cortical neuropeptide, cortistatin-14, impairs post-training memory processing. *Brain*

- Res 1997; 775(1-2): 250-2.
[http://dx.doi.org/10.1016/S0006-8993\(97\)01084-6](http://dx.doi.org/10.1016/S0006-8993(97)01084-6)
- [200] De Lecea L, del Rio JA, Criado JR, *et al.* Cortistatin is expressed in a distinct subset of cortical interneurons. *J Neurosci* 1997; 17(15): 5868-80.
<http://dx.doi.org/10.1523/JNEUROSCI.17-15-05868.1997>
- [201] Dalm VA, Van Hagen PM, Van Koetsveld PM, *et al.* Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. *J Clin Endocrinol Metab* 2003; 88(1): 270-6.
<http://dx.doi.org/10.1210/jc.2002-020950>
- [202] Dalm VASH, Van Hagen PM, Van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DHJ, van der, Lely A.; J. Lamberts, S.; Hofland, LJ. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. *Am J Physiol Endocrinol Metab* 2003; 285(2): 344-53.
<http://dx.doi.org/10.1152/ajpendo.00048.2003>
- [203] Duran-Prado M, Morell M, Delgado-Maroto V, *et al.* Culler.; Hernandez-Cortes P.; O'Valle F.; Delgado M. Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation. *Circ Res* 2013; 112(11): 1444-55.
<http://dx.doi.org/10.1161/CIRCRESAHA.112.300695>
- [204] Gonzalez-Rey E, Delgado M. Cortistatin as a potential multistep therapeutic agent for inflammatory disorders. *Drug News Perspect* 2006; 19(7): 393-9.
<http://dx.doi.org/10.1358/dnp.2006.19.7.1021490>
- [205] Capuano A, Currò D, Navarra P, Tringali G. Cortistatin modulates calcitonin gene-related peptide release from neuronal tissues of rat. Comparison with somatostatin. *Peptides* 2011; 32(1): 138-43.
<http://dx.doi.org/10.1016/j.peptides.2010.09.018>
- [206] De Lecea L, Criado JR, Prospero-Garcia O, *et al.* A cortical neuropeptide with neuronal depressant and sleep-modulating properties. *Nature* 1996; 381(6579): 242-5.
<http://dx.doi.org/10.1038/381242a0>
- [207] Liu Y, Zhou YB, Zhang GG, *et al.* Cortistatin attenuates vascular calcification in rats. *Regul Pept* 2010; 159(1-3): 35-43.
<http://dx.doi.org/10.1016/j.regpep.2009.09.005>
- [208] Delgado M, Gonzalez-Rey E. Role of Cortistatin in the Stressed Immune System 2017.
- [209] Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. *Nat Rev Immunol* 2007; 7(1): 52-63.
<http://dx.doi.org/10.1038/nri1984>
- [210] Faló CP, Benitez R, Caro M, *et al.* The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. *Pharmaceutics* 2021; 13(7): 947.
<http://dx.doi.org/10.3390/pharmaceutics13070947>
- [211] Souza-Moreira L, Morell M, Delgado-Maroto V, *et al.* Paradoxical effect of cortistatin treatment and its deficiency on experimental autoimmune encephalomyelitis. *J Immunol* 2013; 191(5): 2144-54.
<http://dx.doi.org/10.4049/jimmunol.1300384>
- [212] Pääkkönen V, Bleicher F, Carrouel F, *et al.* General expression profiles of human native odontoblasts and pulp-derived cultured odontoblast-like cells are similar but reveal differential neuropeptide expression levels. *Arch Oral Biol* 2009; 54(1): 55-62.
<http://dx.doi.org/10.1016/j.archoralbio.2008.09.004>
- [213] Ichikawa H, Helke CJ. Distribution, origin and plasticity of galanin-immunoreactivity in the rat carotid body. *Neuroscience* 1993; 52(3): 757-67.
[http://dx.doi.org/10.1016/0306-4522\(93\)90424-E](http://dx.doi.org/10.1016/0306-4522(93)90424-E)
- [214] Melander T, Hökfelt T, Rökaeus A. Distribution of galaninlike immunoreactivity in the rat central nervous system. *J Comp Neurol* 1986; 248(4): 475-517.
<http://dx.doi.org/10.1002/cne.902480404>
- [215] Skofitsch G, Jacobowitz DM. Galanin-like immunoreactivity in capsaicin sensitive sensory neurons and ganglia. *Brain Res Bull* 1985; 15(2): 191-5.
[http://dx.doi.org/10.1016/0361-9230\(85\)90135-2](http://dx.doi.org/10.1016/0361-9230(85)90135-2)
- [216] Lang R, Gundlach AL, Holmes FE, *et al.* Physiology, Signaling, and Pharmacology of Galanin Peptides and Receptors: Three Decades of Emerging Diversity. *Pharmacol Rev* 2015; 67(1): 118-75.
<http://dx.doi.org/10.1124/pr.112.006536>
- [217] Bauer JW, Lang R, Jakab M, Kofler B. Galanin family of peptides in skin function. *Exp Suppl* 2012; 2010(102): 51-9.
http://dx.doi.org/10.1007/978-3-0346-0228-0_5
- [218] Lang R, Kofler B. The galanin peptide family in inflammation. *Neuropeptides* 2011; 45(1): 1-8.
<http://dx.doi.org/10.1016/j.npep.2010.10.005>
- [219] Hobson S-A, Holmes FE, Kerr NCH, Pope RJP, Wynick D. Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour. *J Neurochem* 2006; 99(3): 1000-10.
<http://dx.doi.org/10.1111/j.1471-4159.2006.04143.x>
- [220] Brancheck TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. *Trends Pharmacol Sci* 2000; 21(3): 109-17.
[http://dx.doi.org/10.1016/S0165-6147\(00\)01446-2](http://dx.doi.org/10.1016/S0165-6147(00)01446-2)
- [221] Habert-Ortoli E, Amiranoff B, Loquet I, Laburthe M, Mayaux JF. Molecular cloning of a functional human galanin receptor. *Proc Natl Acad Sci USA* 1994; 91(21): 9780-3.
<http://dx.doi.org/10.1073/pnas.91.21.9780>
- [222] Howard AD, Tan C, Shiao LL, et al. Molecular cloning and characterization of a new receptor for galanin. *FEBS Lett* 1997; 405(3): 285-90.
[http://dx.doi.org/10.1016/S0014-5793\(97\)00196-8](http://dx.doi.org/10.1016/S0014-5793(97)00196-8)
- [223] Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. *Biochemistry* 1998; 37(19): 6711-7.
<http://dx.doi.org/10.1021/bi9728405>
- [224] Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. *Pharmacol Ther* 2007; 115(2): 177-207.
<http://dx.doi.org/10.1016/j.pharmthera.2007.05.009>
- [225] Yu L-C, Xu S-L, Xiong W, Lundberg T. The effect of galanin on wide-dynamic range neuron activity in the spinal dorsal horn of rats. *Regul Pept* 2001; 101(1): 179-82.
[http://dx.doi.org/10.1016/S0167-0115\(01\)00287-7](http://dx.doi.org/10.1016/S0167-0115(01)00287-7)
- [226] Liu H-X, Hökfelt T. The participation of galanin in pain processing at the spinal level. *Trends Pharmacol Sci* 2002; 23(10): 468-74.
[http://dx.doi.org/10.1016/S0165-6147\(02\)02074-6](http://dx.doi.org/10.1016/S0165-6147(02)02074-6)
- [227] Hua X-Y, Hayes CS, Hofer A, *et al.* Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5. *J Pharmacol Exp Ther* 2004; 308(2): 574-82.
<http://dx.doi.org/10.1124/jpet.103.058289>
- [228] Wiesenfeld-Hallin Z, Xu X-J, Crawley JN, Hökfelt T. Galanin and spinal nociceptive mechanisms: Recent results from transgenic and knock-out models. *Neuropeptides* 2005; 39(3): 207-10.
<http://dx.doi.org/10.1016/j.npep.2004.12.017>
- [229] Xu X-J, Hökfelt T, Wiesenfeld-Hallin Z. Galanin - 25 years with a multitalented neuropeptide. *Cell Mol Life Sci* 2008; 65(12): 1813-9.
<http://dx.doi.org/10.1007/s00018-008-8152-9>
- [230] Jin W-Y, Liu Z, Liu D, Yu L-C. Antinociceptive effects of galanin in the central nucleus of amygdala of rats, an involvement of opioid receptors. *Brain Res* 2010; 1320: 16-21.
<http://dx.doi.org/10.1016/j.brainres.2009.12.060>
- [231] Endoh T, Sato D, Wada Y, *et al.* Galanin inhibits calcium channels via Gai-protein mediated by GalR1 in rat nucleus tractus solitarius. *Brain Res* 2008; 1229: 37-46.
<http://dx.doi.org/10.1016/j.brainres.2008.06.036>
- [232] Hao JX, Shi TJ, Xu IS, *et al.* Intrathecal galanin alleviates allodynia-like behaviour in rats after partial peripheral nerve injury. *Eur J Neurosci* 1999; 11(2): 427-32.
<http://dx.doi.org/10.1046/j.1460-9568.1999.00447.x>
- [233] Yang Y, Zhang Y, Li XH, *et al.* Involvements of galanin and its receptors in antinociception in nucleus accumbens of rats with inflammatory pain. *Neurosci Res* 2015; 97: 20-5.

- <http://dx.doi.org/10.1016/j.neures.2015.03.006>
- [234] Reimann W, Englberger W, Friderichs E, Selve N, Willfert B. Spinal antinociception by morphine in rats is antagonized by galanin receptor antagonists. *Naunyn Schmiedebergs Arch Pharmacol* 1994; 350(4): 380-6. <http://dx.doi.org/10.1007/BF00178955>
- [235] Wiesenfeld-Hallin Z, Xu XJ, Langel U, Bedecs K, Hökfelt T, Bartfai T. Galanin-mediated control of pain: enhanced role after nerve injury. *Proc Natl Acad Sci USA* 1992; 89(8): 3334-7. <http://dx.doi.org/10.1073/pnas.89.8.3334>
- [236] Brumovsky P, Mennicken F, O'donnell D, Hökfelt T. Differential distribution and regulation of galanin receptors- 1 and -2 in the rat lumbar spinal cord. *Brain Res* 2006; 1085(1): 111-20. <http://dx.doi.org/10.1016/j.brainres.2006.02.088>
- [237] Landry M, Bouali-Benazzouz R, André C, *et al.* Galanin receptor 1 is expressed in a subpopulation of glutamatergic interneurons in the dorsal horn of the rat spinal cord. *J Comp Neurol* 2006; 499(3): 391-403. <http://dx.doi.org/10.1002/cne.21109>
- [238] Yue H-Y, Fujita T, Kumamoto E. Biphasic modulation by galanin of excitatory synaptic transmission in substantia gelatinosa neurons of adult rat spinal cord slices. *J Neurophysiol* 2011; 105(5): 2337-49. <http://dx.doi.org/10.1152/jn.00991.2010>
- [239] Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. *Oncogene* 2000; 19(37): 4199-209. <http://dx.doi.org/10.1038/sj.onc.1203777>
- [240] Xiong W, Gao L, Sapra A, Yu L-C. Antinociceptive role of galanin in the spinal cord of rats with inflammation, an involvement of opioid systems. *Regul Pept* 2005; 132(1): 85-90. <http://dx.doi.org/10.1016/j.regpep.2005.09.002>
- [241] Suzuki H, Iwanaga T, Yoshie H, *et al.* Expression of galanin receptor-1 (GALR1) in the rat trigeminal ganglia and molar teeth. *Neurosci Res* 2002; 42(3): 197-207. [http://dx.doi.org/10.1016/S0168-0102\(01\)00323-6](http://dx.doi.org/10.1016/S0168-0102(01)00323-6)
- [242] Byers MR. Dental sensory receptors. *Int Rev Neurobiol* 1984; 25: 39-94. [http://dx.doi.org/10.1016/S0074-7742\(08\)60677-7](http://dx.doi.org/10.1016/S0074-7742(08)60677-7)
- [243] Kerr BJ, Gupta Y, Pope R, Thompson SWN, Wynick D, McMahon SB. Endogenous galanin potentiates spinal nociceptive processing following inflammation. *Pain* 2001; 93(3): 267-77. [http://dx.doi.org/10.1016/S0304-3959\(01\)00326-8](http://dx.doi.org/10.1016/S0304-3959(01)00326-8)
- [244] Reeve AJ, Walker K, Urban L, Fox A. Excitatory effects of galanin in the spinal cord of intact, anaesthetized rats. *Neurosci Lett* 2000; 295(1-2): 25-8. [http://dx.doi.org/10.1016/S0304-3940\(00\)01576-7](http://dx.doi.org/10.1016/S0304-3940(00)01576-7)
- [245] Liu F, Yajima T, Wang M, Shen J-F, Ichikawa H, Sato T. Effects of trigeminal nerve injury on the expression of galanin and its receptors in the rat trigeminal ganglion. *Neuropeptides* 2020; 84102098 <http://dx.doi.org/10.1016/j.npep.2020.102098>
- [246] Liu HX, Brumovsky P, Schmidt R, *et al.* Dios mío, C.; Hökfelt, T. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. *Proc Natl Acad Sci USA* 2001; 98(17): 9960-4. <http://dx.doi.org/10.1073/pnas.16129359>
- [247] Jimenez-Andrade JM, Zhou S, Yamaxni A, Valencia de Ita S, Castañeda-Hernandez G, Carlton SM. Mechanism by which peripheral galanin increases acute inflammatory pain. *Brain Res* 2005; 1056(2): 113-7. <http://dx.doi.org/10.1016/j.brainres.2005.07.007>
- [248] Hulse RP, Donaldson LF, Wynick D. Peripheral galanin receptor 2 as a target for the modulation of pain. *Pain Res Treat* 2012; 2012545386 <http://dx.doi.org/10.1155/2012/545386>
- [249] Pert A, Moody TW, Pert CB, Dewald LA, Rivier J. Bombesin: receptor distribution in brain and effects on nociception and locomotor activity. *Brain Res* 1980; 193(1): 209-20. [http://dx.doi.org/10.1016/0006-8993\(80\)90958-0](http://dx.doi.org/10.1016/0006-8993(80)90958-0)
- [250] Zhang HP, Xiao Z, Cilz NI, Hu B, Dong H, Lei S. Bombesin facilitates GABAergic transmission and depresses epileptiform activity in the entorhinal cortex. *Hippocampus* 2014; 24(1): 21-31. <http://dx.doi.org/10.1002/hipo.22191>
- [251] Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. *Pharmacol Rev* 2008; 60(1): 1-42. <http://dx.doi.org/10.1124/pr.107.07108>
- [252] King B, Jones M, Ewart W. Immunocytochemical localization of bombesin-like peptides in afferent cranial nerves and brain stem nuclei in rats. *Ann N Y Acad Sci* 1988; 547: 447-7. <http://dx.doi.org/10.1111/j.1749-6632.1988.tb23913.x>
- [253] Aubeux D, Peters O, Hosseinpour S, *et al.* Specialized pro-resolving lipid mediators in endodontics: a narrative review. *BMC Oral Health* 2021; 21(1): 276. <http://dx.doi.org/10.1186/s12903-021-01619-8>
- [254] Cotti E, Ideo F, Pedrazzini A, Bardini G, Musu D, Kantarci A. Proresolving mediators in endodontics: A systematic review. *J Endod* 2021; 47(5): 711-20. <http://dx.doi.org/10.1016/j.joen.2021.01.008>
- [255] Dalli J. Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections? *Mol Aspects Med* 2017; 58: 12-20. <http://dx.doi.org/10.1016/j.mam.2017.03.007>
- [256] Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. *Mol Aspects Med* 2017; 58: 114-29. <http://dx.doi.org/10.1016/j.mam.2017.03.005>
- [257] Fattori V, Zaninelli TH, Rasquel-Oliveira FS, Casagrande R, Verri WA. Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs. *Pharmacol Res* 2020; 151104549 <http://dx.doi.org/10.1016/j.phrs.2019.104549>
- [258] Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging Roles of Resolvins in the Resolution of Inflammation and Pain. *Trends Neurosci* 2011; 34(11): 599-609. <http://dx.doi.org/10.1016/j.tins.2011.08.005>
- [259] Sommer C, Birklein F. Fighting off pain with resolvins. *Nat Med* 2010; 16(5): 518-20. <http://dx.doi.org/10.1038/nm0510-518>
- [260] Yoo S, Lim JY, Hwang SW. Resolvins: Endogenously-generated potent painkilling substances and their therapeutic perspectives. *Curr Neuropharmacol* 2013; 11(6): 664-76. <http://dx.doi.org/10.2174/1570159X11311060009>
- [261] Roh J, Go EJ, Park JW, Kim YH, Park C. Resolvins: Potent Pain Inhibiting Lipid Mediators via Transient Receptor Potential Regulation. *Front Cell Dev Biol* 2020; 8584206 <http://dx.doi.org/10.3389/fcell.2020.58420>
- [262] Xu ZZ, Zhang L, Liu T, *et al.* Resolvins RvE1 and RvD1 Attenuate Inflammatory Pain via Central and Peripheral Actions. *Nat Med* 2010; 16(5): 592-7. <http://dx.doi.org/10.1038/nm.2123>
- [263] Leuti A, Fava M, Pellegrini N, Maccarrone M. Role of specialized pro-resolving mediators in neuropathic pain. *Front Pharmacol* 2021; 12717993 <http://dx.doi.org/10.3389/fphar.2021.71799>
- [264] Zhang LY, Jia MR, Sun T. The roles of special proresolving mediators in pain relief. *Rev Neurosci* 2018; 29(6): 645-60. <http://dx.doi.org/10.1515/revneuro-2017-0074>
- [265] Tao X, Lee MS, Donnelly CR, Ji R. Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain. *Neurotherapeutics* 2020; 17(3): 886-99. <http://dx.doi.org/10.1007/s13311-020-00892-9>
- [266] Fredman G, Serhan C. Specialized pro-resolving mediators: wiring the circuitry of effector immune and tissue homeostasis. *Endod Topics* 2011; 24(1): 39-58. <http://dx.doi.org/10.1111/etp.12010>

- [267] Serhan CN, Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. *Curr Opin Pharmacol* 2013; 13(4): 32-40.
<http://dx.doi.org/10.1016/j.coph.2013.05.012>
- [268] Keinan D, Leigh NJ, Nelson JW, de Oleo L, Baker O. Understanding resolvin signaling pathways to improve oral health. *Int J Mol Sci* 2013; 14(3): 5501-18.
<http://dx.doi.org/10.3390/ijms14035501>
- [269] Sommer C, Birklein F. Resolvins and inflammatory pain. *F1000 Med Rep* 2011; 3: 19.
<http://dx.doi.org/10.3410/M3-19>
- [270] Khan J, Puchimada B, Kadouri D, Zusman T, Javed F, Eliav E. The anti-nociceptive effects of *Porphyromonas gingivalis* lipopolysaccharide. *Arch Oral Biol* 2019; 102: 193-8.
<http://dx.doi.org/10.1016/j.archoralbio.2019.04.012>
- [271] Deng L, Chiu I. Microbes and pain. *PLoS Pathog* 2021; 17e1009398
<http://dx.doi.org/10.1371/journal.ppat.1009398>
- [272] Ko Yj, Ky K, Ky K, et al. The Anti-Inflammatory Effect of Human Telomerase-Derived Peptide on *P. gingivalis* Lipopolysaccharide-Induced Inflammatory Cytokine Production and Its Mechanism in Human Dental Pulp Cells. *Mediators Inflamm* 2015; 2015: 385127.
<http://dx.doi.org/10.1155/2015/385127>
- [273] Martin FE, Nadkarni MA, Jacques NA, Hunter N. Quantitative microbiological study of human carious dentine by culture and real-time PCR: association of anaerobes with histopathological changes in chronic pulpitis. *J Clin Microbiol* 2002; 40(5): 1698-704.
<http://dx.doi.org/10.1128/JCM.40.5.1698-1704.2002>
- [274] Sundqvist G, Johansson E, Sjögren U. Prevalence of black-pigmented bacteroides species in root canal infections. *J Endod* 1989; 15(1): 13-9.
[http://dx.doi.org/10.1016/S0099-2399\(89\)80092-5](http://dx.doi.org/10.1016/S0099-2399(89)80092-5)
- [275] Milshteyn A, Colosimo DA, Brady SF. Accessing bioactive natural products from the human microbiome. *Cell Host Microbe* 2018; 23(6): 725-36.
<http://dx.doi.org/10.1016/j.chom.2018.05.013>
- [276] Structure, function and diversity of the healthy human microbiome. *Nature* 2012; 486(7402): 207-14.
<http://dx.doi.org/10.1038/nature11234>
- [277] Qin J, Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.; Manichanh, C.; Nielsen, T.; Pons, N.; Levénez, F.; Yamada, T.; Mende, D.; Li, J.; Xu, J.; Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, H.; Zheng, H.; Xie, Y.; Lepage, P.; Bertalan, M.; Batto, J.; Hansen, J.; Le Paslier, D.; Linneberg, A.; Nielsen, HB.; Pelletier, E.; Renault, P.; Sicheritz-Ponten, T.; Turner, K.; Zhu, H.; Yu, C.; Li, S.; Zhou, Y.; Li, Y.; Xiuqing, Z.; Li, S.; Yang, H.; Wang, J.; Brunak, S.; Guarner, F.; Kristiansen, K.; Pedersen, O.; Weissenbach, J.; MetaHIT, C.; Bork, P.; Ehrlich, D.; Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; 464(7285): 59-65.
<http://dx.doi.org/10.1038/nature08821>
- [278] O'Mahony L, McCarthy J, Kelly P, et al. *Lactobacillus* and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology* 2005; 128(3): 541-51.
<http://dx.doi.org/10.1053/j.gastro.2004.11.050>
- [279] Verdú EF, Bercik P, Verma-Gandhu M, et al. *Rochat.*; Collins, SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. *Gut* 2006; 55(2): 182-90.
<http://dx.doi.org/10.1136/gut.2005.066100>
- [280] Rousseaux C, Thuru X, Gelot A, et al. *Lactobacillus acidophilus* modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med* 2007; 13(1): 35-7.
<http://dx.doi.org/10.1038/nm1521>
- [281] Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. γ -Aminobutyric acid production by culturable bacteria from the human intestine. *J Appl Microbiol* 2012; 113(2): 411-7.
<http://dx.doi.org/10.1111/j.1365-2672.2012.05344.x>
- [282] Duranti S, Ruiz L, Lugli GA, et al. Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA. *Sci Rep* 2020; 10(1): 14112.
<http://dx.doi.org/10.1038/s41598-020-70986-z>
- [283] Pokusaeva K, Johnson C, Luk B, et al. lugo.; La mayor.; Mori-Akiyama Y.; Hollister EB.; dan sm.; Shi XZ.; Engler DA.; Savidge T.; Versalovich J. GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc* 2017; 29(1): e12904.
<http://dx.doi.org/10.1111/nmo.12904>
- [284] Donnelly CR, Chen O, Ji RR. How Do Sensory Neurons Sense Danger Signals? *Trends Neurosci* 2020; 43(10): 822-38.
<http://dx.doi.org/10.1016/j.tins.2020.07.008>
- [285] Chiu IM, Heesters BA, Ghasemlou N, et al. Wardenburg.; Hwang, S.; Carroll, M.; Woolf, C. Bacteria activate sensory neurons that modulate pain and inflammation. *Nature* 2013; 501(7465): 52-7.
<http://dx.doi.org/10.1038/nature12479>
- [286] Diogenes A, Ferraz CCR, Akopian AN, Henry MA, Hargreaves KM. LPS sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. *J Dent Res* 2011; 90(6): 759-64.
<http://dx.doi.org/10.1177/0022034511400225>
- [287] Gong L, Gao F, Li J, et al. Oxytocin-induced membrane hyperpolarization in pain-sensitive dorsal root ganglia neurons mediated by Ca(2+)/nNOS/NO/KATP pathway. *Neuroscience* 2015; 289: 417-28.
<http://dx.doi.org/10.1016/j.neuroscience.2014.12.058>
- [288] Yu SQ, Lundeberg T, Yu LC. Involvement of oxytocin in spinal antinociception in rats with inflammation. *Brain Res* 2003; 983(1-2): 13-22.
[http://dx.doi.org/10.1016/S0006-8993\(03\)03019-1](http://dx.doi.org/10.1016/S0006-8993(03)03019-1)
- [289] Ando M, Hayashi Y, Hitomi S, et al. Oxytocin-Dependent Regulation of TRPs Expression in Trigeminal Ganglion Neurons Attenuates Orofacial Neuropathic Pain following Infraorbital Nerve Injury in Rats. *Int J Mol Sci* 2020; 21(23): 9173.
<http://dx.doi.org/10.3390/ijms21239173>
- [290] Warfvinge K, Krause DN, Maddahi A, et al. Oxytocin as a regulatory neuropeptide in the trigeminovascular system: Localization, expression and function of oxytocin and oxytocin receptors. *Cephalalgia* 2020; 40(12): 1283-95.
<http://dx.doi.org/10.1177/0333102420929027>
- [291] Tzabazis A, Mechanic J, Miller J, et al. Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. *Cephalalgia* 2016; 36(10): 943-50.
<http://dx.doi.org/10.1177/0333102415618615>
- [292] Schorsch-Petcu A, Sotocinal S, Ciura S, et al. Oxytocin-Induced Analgesia and Scratching Are Mediated by the Vasopressin-1A Receptor in the Mouse. *J Neurosci* 2010; 30(24): 8274-84.
<http://dx.doi.org/10.1523/JNEUROSCI.1594-10.2010>
- [293] Qiu F, Qiu CY, Cai H, et al. Oxytocin inhibits the activity of acid-sensing ion channels through the vasopressin, V1A receptor in primary sensory neurons. *Br J Pharmacol* 2014; 171(12): 3065-76.
<http://dx.doi.org/10.1111/bph.12635>
- [294] Manzano-García A, González-Hernández A, Tello-García IA, Martínez-Lorenzana G, Condés-Lara M. The role of peripheral vasopressin 1A and oxytocin receptors on the subcutaneous vasopressin antinociceptive effects. *Eur J Pain* 2018; 22(3): 511-26.
<http://dx.doi.org/10.1002/ejp.1134>
- [295] Kubo A, Shinoda M, Katagiri A, et al. Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia. *Pain* 2017; 158(4): 649-59.
<http://dx.doi.org/10.1097/j.pain.0000000000000808>
- [296] Qiu F, Hu WP, Yang ZF. Enhancement of GABA-activated currents by arginine vasopressin in rat dorsal root ganglion neurons. *Sheng Li Xue Bao* 2014; 66(6): 647-57.
<http://dx.doi.org/10.13294/j.aps.2014.0077>
- [297] Nersesyan Y, Demirkhanyan L, Cabezas-Bratesco D, et al. Oxytocin modulates nociception as an agonist of pain-sensing

- TRPV1. *Cell Rep* 2017; 21(6): 1681-91.
<http://dx.doi.org/10.1016/j.celrep.2017.10.063>
- [298] Lyu RM, Huang XF, Zhang Y, *et al.* Phoenixin: a novel peptide in rodent sensory ganglia. *Neuroscience* 2013; 250: 622-31.
<http://dx.doi.org/10.1016/j.neuroscience.2013.07.057>
- [299] Sun G, Ren Q, Bai L, Zhang L. Phoenixin-20 suppresses lipopolysaccharide-induced inflammation in dental pulp cells. *Chem Biol Interact* 2020; 318:108971
<http://dx.doi.org/10.1016/j.cbi.2020.108971>
- [300] König M, Zimmer AM, Steiner H, Holmes F, Crawley.; Brownstein, M.; Zimmer, A. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. *Nature* 1996; 383(6600): 535-8.
<http://dx.doi.org/10.1038/383535a0>
- [301] Rougeot C, Robert F, Menz L, Bisson JF, Messaoudi M. Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. *J Physiol Pharmacol* 2010; 61(4): 483-90.
- [302] Wisner A, Dufour E, Messaoudi M, *et al.* Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. *Proc Natl Acad Sci USA* 2006; 103(47): 17979-84.
<http://dx.doi.org/10.1073/pnas.0605865103>
- [303] Ozdogan MS, Gungormus M, Yusufoglu S, Ertem SY, Sonmez C, Orhan M. Salivary opiorphin in dental pain: A potential biomarker for dental disease. *Arch Oral Biol* 2019; 99: 15-21.
<http://dx.doi.org/10.1016/j.archoralbio.2018.12.006>
- [304] Álvarez-Vásquez JL, Bravo-Guapisaca MI, Gavidia-Pazmiño JF, Intriago-Morales RV. Adipokines in dental pulp: Physiological, pathological, and potential therapeutic roles. *J Oral Biosci* 2022; 64(1): 59-70.
<http://dx.doi.org/10.1016/j.job.2021.11.002>
- [305] Lehr S, Hartwig S, Lamers D. Identification and validation of novel adipokines released from primary human adipocytes 2012.
- [306] Kritikou K, Totan A, Tanase M, Vinereanu A, Totan A, Spinu C. linca, R.; Miricescu, D.; Stanescu-Spinu J.; Greabu M. Biochemical Mapping of the Inflamed Human Dental Pulp. *Appl Sci (Basel)* 2021; 11(21): 10395.
<http://dx.doi.org/10.3390/app112110395>
- [307] Furman D, Campisi J, Verdin E, *et al.* Chronic inflammation in the etiology of disease across the life span. *Nat Med* 2019; 25(12): 1822-32.
<http://dx.doi.org/10.1038/s41591-019-0675-0>
- [308] Liu L, Wang T, Huang D, Song D. Comprehensive analysis of differentially expressed genes in clinically diagnosed irreversible pulpitis by multiplatform data integration using a robust rank aggregation approach. *J Endod* 2021; 47(9): 1365-75.
<http://dx.doi.org/10.1016/j.joen.2021.07.007>
- [309] Chen M, Zeng J, Yang Y, Wu B. Diagnostic biomarker candidates for pulpitis revealed by bioinformatics analysis of merged microarray gene expression datasets. *BMC Oral Health* 2020; 20(1): 279.
<http://dx.doi.org/10.1186/s12903-020-01266-5>
- [310] Fouad AF, Khan AA, Silva RM, Kang MK. Genetic and epigenetic characterization of pulpal and periapical inflammation. *Front Physiol* 2020; 11: 21.
<http://dx.doi.org/10.3389/fphys.2020.0002>
- [311] Galicia JC, Henson BR, Parker JS, Khan AA. Gene expression profile of pulpitis. *Genes Immun* 2016; 17(4): 239-43.
<http://dx.doi.org/10.1038/gene.2016.14>
- [312] Ricucci D, Loghini S, Siqueira JF. Correlation between clinical and histologic pulp diagnoses. *J Endod* 2014; 40: 1932-9.
<http://dx.doi.org/10.1016/j.joen.2014.08.010>
- [313] Laine M, Ventä I, Hyrkäs T, Ma J, Konttinen YT. Chronic inflammation around painless partially erupted third molars. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003; 95(3): 277-82.
<http://dx.doi.org/10.1067/moe.2003.86>
- [314] Marciani RD. Is there pathology associated with asymptomatic third molars? *J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg* 2012; 70(9) (Suppl. 1): S15-9.
<http://dx.doi.org/10.1016/j.joms.2012.04.025>
- [315] Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet Lond Engl* 2005; 366(9499): 1809-20.
[http://dx.doi.org/10.1016/S0140-6736\(05\)67728-8](http://dx.doi.org/10.1016/S0140-6736(05)67728-8)
- [316] Paloma de Oliveira B, Câmara AC, Aguiar CM. Prevalence of asymptomatic apical periodontitis and its association with coronary artery disease in a Brazilian subpopulation. *Acta Stomatol Croat* 2017; 51(2): 106-12.
<http://dx.doi.org/10.15644/asc51/2/3>
- [317] Karteva T, Manchorova-Veleva N. Biomarker for asymptomatic apical periodontitis in gingival crevicular fluid: aMMP-8. *Eur J Dent* 2020; 14(2): 239-44.
<http://dx.doi.org/10.1055/s-0040-1709827>
- [318] Buonavoglia A, Latronico F, Pirani C, Greco MF, Corrente M, Prati C. Symptomatic and asymptomatic apical periodontitis associated with red complex bacteria: clinical and microbiological evaluation. *Odontology* 2013; 101(1): 84-8.
<http://dx.doi.org/10.1007/s10266-011-0053-y>
- [319] Bennett DLH, Woods CG. Painful and painless channelopathies. *Lancet Neurol* 2014; 13(6): 587-99.
[http://dx.doi.org/10.1016/S1474-4422\(14\)70024-9](http://dx.doi.org/10.1016/S1474-4422(14)70024-9)
- [320] Nahorski MS, Chen YC, Woods CG. New Mendelian Disorders of Painlessness. *Trends Neurosci* 2015; 38(11): 712-24.
<http://dx.doi.org/10.1016/j.tins.2015.08.010>
- [321] Simonetti M, Kuner R. Locus revealed: Painlessness *via* loss of Nav1.7 at central terminals of sensory neurons. *Neuron* 2021; 109(9): 1413-6.
<http://dx.doi.org/10.1016/j.neuron.2021.04.011>
- [322] Ziegler D, Landgraf R, Lobmann R, *et al.* Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). *Diabetes Res Clin Pract* 2018; 139: 147-54.
<http://dx.doi.org/10.1016/j.diabres.2018.02.043>
- [323] Testa G, Cattaneo A, Capsoni S. Understanding pain perception through genetic painlessness diseases: The role of NGF and proNGF. *Pharmacol Res* 2021; 169:105662.
<http://dx.doi.org/10.1016/j.phrs.2021.105662>
- [324] Goto M, Nakanaga K, Aung T, *et al.* Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. *Am J Pathol* 2006; 168(3): 805-11.
<http://dx.doi.org/10.2353/ajpath.2006.050375>
- [325] Amodio A, De Marchi G, de Pretis N, *et al.* Painless chronic pancreatitis. *Dig Liver Dis* 2020; 52(11): 1333-7.
<http://dx.doi.org/10.1016/j.dld.2020.08.040>
- [326] Bhullar FA, Faghieh M, Akshintala VS, Ahmed A, Lobnerc K. afgano, E.; Phillips, A.; Hart, P.; Ramsey, M.; Bick, B.; Kuhlmann, L.; Drewes, A.; Yadav, D.; Olesen, S.; Singh, V. Prevalence of primary painless chronic pancreatitis: A systematic review and meta-analysis. *Pancreatology* 2022; 22(1): 20-9.
<http://dx.doi.org/10.1016/j.pan.2021.11.006>
- [327] Hollenbach M, Barresi L. Shedding light on painless chronic pancreatitis. *Dig Liver Dis* 2020; 52(11): 1331-2.
<http://dx.doi.org/10.1016/j.dld.2020.06.040>